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Emerging epidemic-prone diseases have introduced numerous health and economic challenges in recent
years. Given current knowledge of COVID-19, herd immunity through vaccines alone is unlikely. In
addition, vaccination of the global population is an ongoing challenge. Besides, the questions regarding
the prevalence and the timing of immunization are still under investigation. Therefore, medical treatment
remains essential in the management of COVID-19. Herein, recent advances from beginning observations
of COVID-19 outbreak to an understanding of the essential factors contributing to the spread and
transmission of COVID-19 and its treatment are reviewed. Furthermore, an in-depth discussion on the
epidemiological aspects, clinical symptoms and most efficient medical treatment strategies to mitigate
the mortality and spread rates of COVID-19 is presented.
First draft submitted: 29 April 2021; Accepted for publication: 12 October 2021; Published online:
23 November 2021
Keywords: antibiotics • antimalarial • antiparasitic • corticosteroids • COVID-19 • immunomodulatory drugs

• immunosuppressants • therapeutic drugs

The current epidemic of SARS-CoV-2, the virus that induces illness known as COVID-19, is an important wakeup call for all countries around the world. Given the dire global consequence that outbreaks of emerging diseases
like COVID-19 can trigger, there is an urgent need to improve preparedness for such epidemic-prone diseases.
COVID-19 is not the first global pandemic, and emergence of new epidemic-prone diseases is inevitable due to
poor humanitarian habits.
Since the start of this century, large outbreaks such as COVID-19, Ebola virus, MERS-CoV, SARS-CoV-2
and influenza A virus subtype H1N1 (A/H1N1) have shattered several myths about the global vulnerability to
threats arising from such epidemic-prone diseases [1,2]. For instance, COVID-19 proved how quickly a new virus
could spread around the world. Several broad-scale factors contributed to the quick dissemination of COVID19 in its early phases, including delays and shortage of vaccines, lack of following quarantine procedures, viral
viability at different climates, viral transmission through domestic and international travel, changing diets and
human population growth. These factors have amplified human exposure rates to COVID-19. Although growing
vaccination rates, lockdowns and social distancing have assisted in reducing the spread of COVID-19 in many
countries, lockdown has also negatively impacted the global economy. Although the disease outlook for COVID-19
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Figure 1. Structure of coronavirus and its components. The coronavirus is a virus that contains ribonucleic acid
genome and nucleocapsid phosphoprotein, which causes many respiratory diseases in human beings and various
ranges of diseases in animals. Spike glycoprotein (S-protein) of the coronavirus represents the primary pattern in
entering the host cells.

is more favorable than SARS or H1N1, the number of deaths and confirmed cases of COVID-19 exceeds that of
SARS or H1N1, which makes COVID-19 harder to manage in comparison with other viruses.
SARS-CoV-2 (order Nidovirales, family Coronaviridae, subfamily Coronavirinae) is a virus that contains a
single-stranded ribonucleic acid genome and a nucleocapsid phosphoprotein (Figure 1). Binding of SARS-CoV-2
to angiotensin-converting enzyme 2 (ACE2) enables viral entry to the cell and causes many respiratory diseases in
human beings and various ranges of diseases in animals [3].
SARS-CoV-2 can target human cells by the binding of spike glycoprotein (S-protein) to ACE2 receptor, a
membrane-bound carboxypeptidase (Figure 2). ACE2 has a C-terminal collectrin-like domain and an N-terminal
peptidase domain. ACE2 receptors are predominantly located in the apical surface of the lung airway epithelium
and enterocytes of the small intestine [4].
Since ACE2 acts as an entry pathway for viral infection, blocking this receptor through ACE inhibitors and
receptor blockers is promising to prevent viral infection into the lungs and whole body. Also, it has been suggested
that the implementation of human recombinant ACE2 (hr-ACE2) protein would be helpful to saturate viral Sproteins and prevent SARS-CoV-2 cell entrance [4].
According to Figure 2, the binding of SARS-CoV-2 to ACE2 receptors stimulates endocytosis through cell
receptors and subsequently forms endosomes. The viral uncoating process via shedding of the endosome results in
RNA exit from the viral structure. Translation of ssRNA results in the synthesis of viral polypeptides that undergo
the proteolysis process and form non-structured proteins. Recent studies have reported that lopinavir and darunavir
are able to interfere with virility at this stage. These polyproteins encode the replicase-transcriptase complex (RTC).
Subsequently, SARS-CoV-2 synthesizes the ssRNA via the RNA dependent RNA polymerase (RdRp) enzyme. Then
translation results in the fabrication of structural proteins. Finally, viral assembly and release through exocytosis
occur [5]. The schematic view of the SARS-CoV-2 lifecycle stages and mechanism of action is depicted in Figure 2.
Padhi and Tripathi have explored putative drug binding sites in the main protease of SARS-CoV-2. They report
mutation hot spots that may explain probable drug resistance [6]. This team also reported mutations in the S-protein
domain that could reduce the effectiveness of therapeutic agents and increase the infectivity and pathogenicity of
the virus [7].
Coronaviruses are categorized into four subgroups: alpha, beta, delta and gamma. Only alpha and beta may be
transmitted to humans and therefore are characterized as human coronaviruses (HCoVs) [8].
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Figure 2. Schematic view of SARS-CoV-2 lifecycle stages and mechanism of action. SARS-CoV-2 can target human
cells via the binding of spike glycoprotein to ACE2 receptor, which is a membrane-bound carboxypeptidase. After the
binding of SARS-CoV-2 to ACE2 receptors, endocytosis takes place through cell receptors and forms endosomes. Then,
the viral uncoating process results in RNA exit from the viral structure. Translation of ssRNA results in the synthesis of
viral polypeptides that undergo the proteolysis process and form non-structured proteins. These polyproteins can
encode the RTC. After that, SARS-CoV-2 synthesizes the ssRNA via the RdRp enzyme. Then, translation results in the
fabrication of structural proteins. Finally, viral assembly and viral release through exocytosis take place.
ACE2: Angiotensin-converting enzyme 2; RdRp: RNA-dependent RNA polymerase; RTC: Replicase-transcriptase
complex.

In late 2019, new cases of beta coronavirus infections were identified in Wuhan, China. Due to the acute
respiratory symptoms of this recently recognized coronavirus, it was subsequently named SARS-CoV-2, and the
WHO named this new coronavirus disease COVID-19.
Patients infected with this virus show different signs and symptoms in the following organ systems: respiratory,
neurological, gastrointestinal and cardiovascular. The more prevalent symptoms include cough, sore throat, fever,
fatigue, headache, arthralgia, anosmia and ageusia [9].
In less than 14 months from the first reported cases, the virus spread globally. The pandemic became one of
the world’s leading challenges in 2020, with a major impact on the economy and more than 5 million mortalities
worldwide.
Many efforts have been made to develop an efficient vaccine for this viral infection. The main types of COVID19 vaccines could be categorized as mRNA [10,11], viral vectors [12] and protein subunits [13]. To date, at least
three different COVID-19 vaccines have been authorized in the USA, including Moderna COVID-19 vaccine
(mRNA-1273), Pfizer-BioNTech COVID-19 vaccine (BNT162b2) and Johnson & Johnson COVID-19 vaccine
(JNJ-78436735, formerly Ad26.COV2. S). Other COVID-19 vaccines have also been developed and authorized in
other countries, including AstraZeneca COVID-19 in the UK (AZD1222, also known as Covishield); CoronaVac,
BBIBP-CorV and Convidicea (Ad5-nCoV) in China; Sputnik V, EpiVacCorona and CoviVac in Russia; Covaxin
in India; and COVIran Barakat in Iran.
In addition to the vaccines mentioned above, more than 200 additional vaccine candidates are currently in
the development phase, of which more than 60 are under clinical investigation [14]. However, various levels of
efficacy have been reported (i.e., from 50% to 95%). Different approaches to vaccine design and technologies are
likely the culprit. Vaccine distribution started in December 2020. Manufacturing and supplying sufficient doses of
vaccines for 7.8 billion people worldwide, the duration of vaccine protection and vaccine efficiencies are some of
the challenges for healthcare providers worldwide. Additionally, new mutants of COVID-19 with enhanced virility
have been observed, especially in South Africa, India, Brazil and the UK. These new mutants may allude to the
immunity encouraged by the vaccines developed to target initial strains of the SARS-CoV-2 virus.
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As previously mentioned, emerging epidemic-prone diseases in the 21st century have introduced numerous health
and economic challenges, resulting in considerable mortality of the human population. To control and mitigate
COVID-19 and address the immediate and long-term health outcomes, it is imperative to have comprehensive
understanding of the nature of COVID-19 evolution, its mode of action and transmission, the potential ecological
factors influencing its emergence (i.e., whether it represents the re-appearance of a familiar and previously studied
pathogen) and its potential connection to previous events.
As the delta variant of the coronavirus spreads throughout the world, it is essential to develop efficient therapeutic
strategies to protect infected patients against severe illness, hospitalization and death. A guide to understanding the
limiting factors for large-scale trials of therapeutic strategies for COVID-19 treatment albeit the spread of the delta
variant and vaccine hesitancy and refusal is highly encouraged. Given the rapid spread of the delta variant, and
the worldwide economic loss, it is imperative to develop effective therapeutic drugs to treat COVID-19 patients.
Significant research efforts have been invested in the development of therapeutic drugs to treat COVID-19 patients.
It has been a challenging process communicating pandemic-related information, especially amid misinformation,
disinformation, conspiracy theories and politicization. As a result, health communicators are facing difficulties in
coming across as credible, transparent and trustworthy. The delta variant has also dramatically upended recent
progress against the pandemic and is forcing a reset everywhere. In this review article, the authors summarize
the current understanding of COVID-19, such as its epidemiological aspects, clinical symptoms, pathophysiology
and pharmacologic categories, as well as the most efficient medical treatment strategies supported by the NIH
and WHO to help reduce severity and mortality rates. The potential mechanisms of action, dosing, adverse drug
reactions and contraindications are also discussed in detail. Further, the most recent information about COVID-19
transmission and prevention is presented. Finally, research insights, existing knowledge gaps, challenges and future
research direction are described, and a state-of-the-art snapshot of drug-based therapeutic strategies for COVID-19
and the attempts to repurpose various classes of drugs is presented.
Epidemiology
Compared with SARS-CoV, COVID-19 has a robust transmission capacity [15]. Patients with severe symptoms
correspond to enhanced viral spread compared with patients with milder symptoms. Asymptomatically infected
individuals and patients who display no signs of respiratory complications are other potential sources of infection.
COVID-19 is a self-limiting illness, and the recovery period in most patients with mild symptoms lasts 1–
2 weeks [16]. Epidemiological evidence indicates this disease transmits through humans by the basic reproductive
number of 2.2 [17]. It seems that the mortality rate is higher in men than women (4.7% vs 2.8%), and the fatality
rate worsens in patients older than 60 years (3.6%) compared with individuals younger than 40 years (0.2%).
Furthermore, patients with pre-existing comorbidities such as diabetes, hypertension and cardiovascular diseases
show higher fatality rates [18,19].
It is noteworthy that epidemiological trends in the outbreak and fatality rate of COVID-19 vary on a daily
basis and new mutants of the virus were reported in Africa, Brazil and the UK. At the beginning of the pandemic,
China was leading in several diagnosed cases. Still, the incidence progressively increased in other countries, mainly
Europe, the USA and the Middle East [20,21].
Among the diseases caused by coronaviruses, SARS, MERS and COVID-19 are most prevalent, resulting in
severe outcomes in humans. Herein, the root of such diseases and their symptoms are discussed.
SARS

In 2003, SARS was transmitted to humans and other animals (civet cats) by bats. The first infected human was
diagnosed in Guangdong Province, China. Since then, the virus has spread to 26 countries and resulted in more
than 8098 cases, with a fatality rate of 9.6% [22].
Like those of influenza, the symptoms included fever, malaise, myalgia, headache, diarrhea and chills (rigors). In
the first and second weeks of illness, patients experienced a dry cough, shortness of breath, gasping and diarrhea.
In severe cases, the disease often progressed rapidly, leading to respiratory failure and requiring intensive care, such
as supplementary oxygen [23].
MERS

MERS was first diagnosed in Saudi Arabia in September 2012. It infected 124 people and caused 52 deaths. The
clinical manifestations of this disease were respiratory problems such as a sore throat, dry cough and dyspnea. The
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Table 1. Common laboratory test results of complete blood counts and blood chemistry results for COVID-19 patients,
categorized according to increased and decreased levels.
Increased

Decreased

WBC (1.5-×)

Lymphocyte count (0.4×)

Neutrophil count (4.4×)

Albumin (0.8×)

LDH (2.1×)
ALT (1.8×)
Total bilirubin
AST (1.5×)
CRP
Procalcitonin (1.2×)
PT (1.4×)
Creatinine (1.1×)
D-dimer (2.5×)
Cardiac troponin (2.2×)
ALT: Alanine transaminase; AST: Aspartate transaminase; CRP: C-reactive protein; LDH: Lactate dehydrogenase; PT: Prothrombin; WBC: White blood cells.

mortality rate was approximately 60% [24]. In 2018, MERS was transmitted to the Republic of Korea by a passenger
traveling to Kuwait and caused a MERS-CoV outbreak in South Korea [25].
Clinical Symptoms of SARS-CoV-2

Although clinical symptoms are important in diagnosis, no individual symptom has been found to diagnose SARSCoV-2. In less than a week, the symptoms include fever, nasal congestion, cough and fatigue, and other signs related
to upper respiratory infections appear [26]. Some references describe asymptomatic infections and gastrointestinal
(GI) symptoms, especially in young children [27].
In addition to the respiratory manifestations of COVID-19, other complications such as neurologic [4], psychiatric, ophthalmologic, hepatobiliary and cutaneous presentations have been observed [28]. According to different
studies on COVID-19 patients, cardiovascular manifestations, including arrhythmia, myocarditis, myocardial
ischemia and myocardial infarction (MI; type 1 and 2), cardiomyopathy and cardiogenic shock, have also been observed [18,29]. Among the neurologic and ophthalmologic symptoms, anosmia, ageusia, anorexia, fatigue, headache,
dizziness, stroke, myalgias, conjunctivitis and encephalopathy have been reported [9,30–32].
The most common dermatological manifestations presented in COVID-19 patients are urticaria, erythematous
rash, livedo reticularis and petechiae [33,34]. Severe cases progress quickly with respiratory failure due to serious
alveolar damage. Moreover, organ dysfunction can occur, such as acute respiratory distress syndrome (ARDS), acute
kidney injury, acute cardiac injury, shock and death [35].
In a study on patients with mild infection, abnormal laboratory results were obtained, such as increased
levels of the erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), D-dimer and lactate dehydrogenase
(LDH) [34,36]. Studies on patients with severe infections have revealed similar results, including increased values
of white blood cells (WBCs), aspartate aminotransferase (AST), LDH, creatinine, cardiac troponin, D-dimer and
prolactin [37]. Increases in the levels of leukocytes, neutrophils, prothrombin (PT) and alanine aminotransferase
(ALT) have also been reported. However, the values of lymphocytes and albumin decreased to some extent [38,39].
Standard laboratory tests for COVID-19 are summarized in Table 1.
Breakthrough COVID-19 cases

A concerning point in this illness is the possibility of reinfection. Vaccines can stop most people, but not everyone,
from getting sick with COVID-19. Despite having been fully vaccinated, there is still a chance that people can get
infected.
Tillett et al. [40] reported the first COVID-19 reinfection case of a 25-year-old male who had recovered from
COVID-19 and had two consecutive reverse transcription polymerase chain reaction (RT-PCR) tests after the
recovery period. After 48 days from his first positive RT-PCR diagnostic test, he had another positive RT-PCR test.
A SARS-CoV-2 genome sequencing study revealed that both specimens were genetically the same in terms of their
clade (clade 20C) but significantly different in genome sequences. It was reported that the SARS-CoV-2 reinfection
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was worse than the first infection and resulted in oxygen requirement and hospitalization [40]. However, it should
be noted that for the majority of breakthrough cases, patients have experienced mild, ‘cold-like’ symptoms.
To date, the association between immunodeficiency and SARS-CoV-2 reinfections has not been confirmed. The
exact incidence of SARS-CoV-2 reinfection is not clear and, given the vast number of asymptomatic cases, this
rate is likely underreported [41]. The most important point in the differential diagnosis of SARS-CoV-2 reinfection
versus SARS-CoV-2 reactivation would be viral genome sequencing. The former can result in different viral genome
sequences, and the latter had the same genome sequences [41]. In order to assay the association between SARS-CoV-2
reinfection and immune response after the first COVID-19 infection, the level and specificity of anti-S protein
antibody at the time of reinfection should be evaluated [41].
Overview of proposed COVID-19 therapeutic drugs
Despite all efforts, the mortality rate related to COVID-19 is still high. Researchers worldwide are investigating
alternative approaches to fighting the COVID-19 global pandemic. Herein, putative therapeutic agents under investigation for the management of COVID-19 are discussed. Therapeutic agents of various categories – including
antiviral, antimalarial, antiparasitic, anti-inflammatory, mucolytic, immunomodulator, corticosteroid, immunosuppressant, anticoagulant and cardioprotective drugs – have been prescribed to treat COVID-19 patients and
were shown to be efficacious in their recovery. This review will be a new collection in COVID-19 treatment
in continuation of the previous efforts of Farjadian et al. in writing review articles on various pharmaceutical
topics [42–48].
Antiviral agents

Favipiravir
Favipiravir is a purine nucleic acid analog [49] that is converted to the acting form of favipiravir ribofuranosyl5 -triphosphate (T-705-RTP) in vivo [50]. It is widely used to treat influenza A and B, Ebola virus, arenavirus,
bunyavirus, flavivirus and filoviruses [51]. It is an inhibitor of viral RdRp and widely administered in the treatment
of COVID-19 [52]. A recent in vitro study reported that favipiravir demonstrated an inhibitory effect on COVID19 [18].
A clinical trial on 35 patients receiving favipiravir compared with LPV/ritonavir was performed on COVID-19
patients. The first group demonstrated a faster recovery period and shorter clearance time of the virus than the
control group [53]. However, another randomized clinical trial showed that patients who received a 7-day course
of favipiravir had no beneficial clinical symptoms compared with patients of umifenovir but those did improve
clinical symptoms such as cough [54].
Lopinavir/ritonavir
These are protease inhibitors that were first approved in 2000 to prevent HIV infection. Ritonavir also raises
the plasma levels of lopinavir (LPV) by inhibiting cytochrome p 450 (CYP450) [55,56]. With the outbreak of the
R
showed a viral inhibitory effect
SARS virus in 2003, this combined medicine under the brand name of Kaletra
in in vitro studies. The outcomes of LPV-ritonavir treatment for COVID-19 patients were investigated [57]. The
administration of this drug did not display a significant clinical improvement in comparison with that of the
standard group [57].
Remdesivir
Remdesivir was first discovered by Gilead Sciences Company [58]. Also, remdesivir demonstrated a prophylactic
effect on MERS-CoV infection in rhesus monkeys [59]. Remdesivir is an analog of a nucleotide monophosphate
prodrug that is converted to the active form of remdesivir C-adenosine nucleoside triphosphate analog [60]. It
attaches to the RNA polymerase of the virus, interrupting transcription of the virus and inhibiting RdRp enzyme
activity [61,62]. An in vitro study in Vero E6 cells demonstrated the antiviral effects of remdesivir (GS-5734) against
COVID-19. Remdesivir was shown to be capable of inhibiting the virus with higher sensitivity and at a lower
concentration [18].
In a study conducted on patients from the USA, Europe, Canada and Japan, remdesivir improved clinical
manifestations [63]. A recent case study of patients showed that intravenous injection of remdesivir improved
patients’ recovery time and mortality compared with that of placebo [64]. In another study, the duration of
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intravenous remdesivir administration for 5 and 10 days was investigated [65]. No significant difference in the
improvement of clinical symptoms for 5- or 10-day administration was reported [65].
Ribavirin
Ribavirin is another RNA antiviral drug. It received US FDA approval in 1998 to treat chronic hepatitis C (CHC).
According to the primary case study in the USA, the flagship study on ribavirin did not show more benefits in
treating patients than LPV/ritonavir. However, new clinical studies have shown therapeutic effects on patients [66,67].
In general, this drug may be considered a possible treatment for COVID-19, based on its performance in prior
studies on similar diseases [68].
Sofosbuvir
Sofosbuvir is an antiviral that directly targets the RNA of the virus. It is used as a combinatorial therapy with
ribavirin and IFN-α [69] to treat hepatitis C virus (HCV). Prior studies have suggested the curative effect of
sofosbuvir in COVID-19 infections. Molecular modeling and an in vitro study have also confirmed its role in
COVID-19 [70,71].
Umifenovir
Umifenovir is an antiviral drug utilized as a prophylaxis for influenza A and B viruses in Russia and China for
several decades [72]. Umifenovir acts by interfering with the virus’s interaction with host cells, likely by binding to
ACE2 receptors [73].
R
) in comparison with LPV/ritonavir
A clinical study reported that the administration of umifenovir (Arbidol
could be effective, as seen by faster viral clearance compared with patients who received LPV/ritonavir. Based on
R
had a negative viral load, whereas the patients in the
the reports in a 14-day period, all patients receiving Arbidol
LPV group had a positive viral load [69].
Antimalarial agents

Hydroxychloroquine
Chloroquine (CQ) is the standard of care to prevent malaria (Plasmodium falciparum) infection. However, CQ
is limited by an increased risk of high-grade side effects such as cardiac arrhythmias (i.e., QT prolongation).
Hydroxychloroquine (HCQ) has been formulated and found to be less toxic (∼40%). HCQ is now prescribed
as an immune modulator for autoimmune diseases such as systemic lupus erythematosus (SLE) and rheumatoid
arthritis (RA) [74]. An in vitro (Vero E6 cells) study revealed that CQ with half-maximum effective concentration
(EC50 ) of 1.13 μm, half cytotoxic concentration (CC50 ) >100 μm was required to reduce the viral load of COVID19 [18]. Moreover, another in vitro study reported that HCQ had more potent inhibitory effects compared with CQ
in SARS-CoV-2. Both CQ and HCQ prevented the entrance of the virus into the cell through an increase in the
pH value of the endosome and alteration of the glycoside transferase of the SARS ACE2 receptor [75]. Importantly,
an observational study revealed that the combination of HCQ and azithromycin (AZN) enhanced clearance and
improved symptoms in 100% of patients [76].
It was reported that patients receiving high doses of CQ diphosphate lowered mortality rate compared with
patients who received low doses of CQ diphosphate. However, the high-dosage group demonstrated more toxic
effects and lethality compared with the low-dosage group 2M3 [71,77]. In contrast with the result discussed above, QT
elongation was not observed. Significant improvements in symptoms and mortality rate were found in those patients
who received HCQ alone or the combination of AZN and HCQ [78]. However, another study on hospitalized
COVID-19 patients reported that concomitant use of AZN and HCQ led to QT-interval prolongation and
increased risk of mortality [79,80].
Antibiotics

Azithromycin
AZN is a macrolide that is efficacious against Gram-negative and Gram-positive bacteria. It has been used to
treat respiratory (bronchitis and pneumonia), enteric and genitourinary tract infections [81]. Several in vitro studies
have recognized that AZN is effective against Ebola and SARS-Cov-2 with EC50 values of 2.792 and 2.12 μm,
respectively [82]. Furthermore, in an in vitro study, concomitant administration of AZN and HCQ resulted in
a synergistic effect in COVID-19 treatment [76]. However, to date, clinical proof for the success of AZN in
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Table 2. Classification of possible COVID-19 treatments in antiviral and antimalarial categories.
Drug

Administration

Mechanism of action

Contraindication

Major side effects

Ref.

Favipiravir

3200 mg-loading doses for
1 day, continued by 1200 mg
for 2–14 days

RNA polymerase inhibitor

Pregnancy and hypersensitivity

Diarrhea, nausea, increased
serum transaminases and uric
acid decreased in the neutrophil
counts

[84]

LPV /ritonavir

LPV/ritonavir 400 /100 mg
twice daily for 10–14 days

Bind SARS-CoV-2 3C-like
proteinase

Hypersensitivity
(e.g., Stevens-Johnson syndrome,
toxic epidermal necrolysis,
urticaria, erythema multiform
and angioedema) to any of its
ingredients

GI disturbance, headache, liver
dysfunction, glycemia and lipid
perturbances and renal lithiasis

[79]

Remdesivir

200 mg iv. as loading dose
continuous 100 mg for
5–10 days

RdRp inhibitors

Hypersensitivity to any
ingredient

Diarrhea, vomiting, nausea, rash
and liver and kidney injury

[80]

Sofosbuvir

400 mg tablet taken once a
day

Nucleotide analog nonstructural
protein 5B (NS5B) polymerase
inhibitor

Combination therapy for
hepatitis C

Fatigue, nausea, headache and
insomnia

[85]

Ribavirin

400 mg tablet taken every
12 h

Nucleotide analog NS5B
polymerase inhibitor

Combination therapy for chronic
hepatitis C

Fatigue, asthenia, headache,
rigors, fevers, nausea and
myalgia

[57]

Umifenovir
R
)
(Arbidol

200 mg/day for 5–10 days

Inhibit entry into the cell through Hypersensitivity to the drug or
binding SARS-CoV-2 S-protein
any ingredient

Elevation of ALT and AST
leucopenia

[86]

CQ

300 mg every 12 h on day 1,
Increasing the endosome pH and
followed by 300 mg × 2 daily altering the glycoside transferase
for 2–5 days (600–1200 mg for
2–5 days)

Hypersensitivity to
4-aminoquinoline, psoriasis
porphyria retinal or visual field
change

Nausea and vomiting, diarrhea,
blurring of vision, cardiac
toxicity, QT prolongation

[87]

AZN

500 mg orally for 1 day,
continued by 250 mg p.o., on
days 2–5

Hypersensitivity to any
macrolides or ketolides, history
of cholestatic jaundice and
hepatic dysfunction

GI symptom (diarrhea, nausea,
vomiting) elevated ALT, AST,
creatinine

[88]

Inhibition of protein synthesis,
immunomodulatory and
anti-inflammatory effects

ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; AZN: Azithromycine; CQ: Chloroquine; GI: Gastrointestinal; LPV: Lopinavir; QT: prolongation; a measure of delayed
ventricular repolarization, RdRp: RNA dependent RNA polymerase.

COVID-19 treatment is lacking. AZN exerts its effect through hindering protein synthesis by binding to 50S
ribosomal subunit bacteria [77]. However, its antiviral mechanism is not yet known. AZN, like HCQ, increases
the pH of the endosome. Macrolides such as AZN, clarithromycin, erythromycin and fidaxomicin also pose antiinflammatory and immunomodulatory effects by affecting the level of interleukin (e.g. IL-6, IL-8), tumor necrosis
factor, alpha (TNF-α), inhibiting T-helper functions, and reduce the oxidative stress [78]. Cluster of differentiation
147 (CD147) is a transmembrane glycol-protein of the immunoglobulin superfamily that acts as a receptor for
Plasmodium falciparum and SARS-CoV-2 invasion [83]. AZN could prevent Plasmodium falciparum invasion and
has shown efficacy in SARS-CoV-2 infection treatment, likely through ligand/receptor interactions [83]. A possible
mechanism of AZN action to treat COVID-19 in red blood cells has been reported [83]. By decreasing viral
replication and virus release,and increasing levels of IFNs and IFN-stimulated proteins, AZN induces anti-viral
responses in epithelial cells [83]. Influenza A and high glucose levels are prompting CD147 expression, which
suggests a possible relevance for chronic inflammatory syndromes like diabetes, asthma and the upper level of
CD147 in involved patients [83].
In Table 2, the antiviral and antimalarial drugs used in COVID-19 treatment, with descriptions of administration,
mechanisms of action, contradictions and major side effects, are briefly discussed.
Antiparasitics:
Nitazoxanide

Nitazoxanide (NTZ), an antiprotozoal, is the active and oral form of nitrothiazolysalicylamide [89]. It can increase
the intracellular production of alpha and beta IFNs. Previous studies have highlighted the antiviral properties of this
drug against MERS-CoV [90]. Although the mechanism of action of NTZ is still under investigation, new studies
believe that this drug can interfere with viral entry and intracellular proliferation of the Sars-CoV-2 virus. Today,
some researchers point to the combination of NTZ/AZN as a more effective treatment for viral infections [91,92].
Some other researchers believe that combining NTZ with HCQ could effectively combat the SARS-CoV-2 virus [93].
It is also suggested that this drug be used in combination with AZN [91]. However, prolonged drug exposure and the
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toxicity of drug combinations are still not well understood. Nevertheless, the antiviral effect of NTZ against viral
infections of HCV, hepatitis B virus (HBV), influenza and coronavirus has been well established. Additionally, there
are implications of using NTZ for asthma and therefore potential benefits in treating COVID-19 symptoms [8].
Ivermectin
Ivermectin is FDA approved for parasitic infections and tropical diseases. It has been shown that this drug can
inhibit the replication of some ssRNA viruses in vitro, such as dengue virus [19,94,95], yellow fever virus [96] and
Zika virus [97]. It has been proposed that ivermectin can bind to importin α/β1 proteins and reduce the infectivity
of coronaviruses. Consequentially, the viral proteins cannot cross the nuclear membrane, resulting in suppression
of virus replication [98,99]. Despite positive experimental outcomes, it is essential to thoroughly investigate cases
reporting high-grade toxicities, such as neurotoxicity, leakage to the CNS and nerve damage [100–102]. Recently,
the concomitant use of ivermectin and HCQ in treating chemoprophylaxis caused by COVID-19 has been
reported [103].
Anti-inflammatory agents

Colchicine
Colchicine is a pleiotropic anti-inflammatory cytotoxic agent. One of the proposed pathways is to inhibit the
polymerization of microtubules by binding to the tubulin protein. In addition to preventing mitosis, colchicine
prevents neutrophil activation and migration to the site of inflammation. This important anti-inflammatory drug
is commonly utilized to treat several inflammatory diseases such as gout and inflammatory bowel disease (IBD).
Furthermore, several studies have reported efficacy in the treatment of Epstein–Barr virus (EBV) [104], hepatitis
virus [105,106], adenoviral and adeno-associated viral vectors [107] and herpes simplex virus type 1 [108]. A cytokine
storm leading to hypovolemic shock is a severe outcome of COVID-19. One essential aspect of treating such
infectious diseases is to prevent this cytokine storm. In this regard, colchicine can be considered a potential drug for
preventing the overproduction of pro-inflammatory cytokines. More specifically, colchicine is a valuable drug for
various infectious diseases triggered by over-activation of the IL-1/IL-6 pathway [109]. This drug has been shown
to improve other immune-related outcomes in COVID-19 patients, such as acute kidney damage, intravascular
coagulation and heart damage [110]. These cases are often related to disease in organ systems largely inhabited by
endothelial cells [111,112].
Furthermore, viral infections targeting endothelial cells often induce a significant amount of oxidative stress [113].
Colchicine inhibits the oxidative stress. Cascade can be an important option to improve these complications [114].
Additionally, another factor that aggravates COVID-19 symptoms is the increased abundance of neutrophil cells.
As mentioned earlier, colchicine can dampen inflammation by inhibiting the function and migration of these
cells [115]. Several laboratories worldwide are currently examining the effect of this drug in improving COVID-19
infection [116]. In the case of colchicine, not all tests are promising. One study found that colchicine at intracellular
pH may increase the viral load of SARS-CoV-2 and thus increase inflammation, resulting in more severe symptoms
of COVID-19 disease [117].
Nonsteroidal anti-inflammatory drugs

Ibuprofen
Ibuprofen is an NSAID used to suppress inflammation, fever and pain. Research on the effectiveness of this drug
on COVID-19 infection is still in the infancy stage of development. Recent studies have shown that the virus
must bind with the ACE2 receptors to enter eukaryotic cells [118]. The virus attaches to the cell surface through
this receptor. So far, the only logical connection between ibuprofen and the improvement of COVID-19 infection
is the inhibitory effect of this drug on the receptor [119]. However, there is a great deal of disagreement among
countries about using this drug to improve patient conditions. One of the strongest opponents of using this drug
to cure infection caused by COVID-19 is the French scientific community [120]. In France, it is speculated that the
use of this drug will increase ACE2 receptors, which will lead to penetration of the virus into cells. After this report,
use of this drug in France decreased to 80% [120]. Unlike France, however, the UK noted no evidence of increased
vulnerability to COVID-19 infection after taking ibuprofen. However, there are generally some doubts about the
association between altered receptor expression (ACE2) at the cellular level and the risk of COVID-19 [121,122].
According to the UK reports, on using ibuprofen or other NSAIDs to treat infection with COVID-19, the risk
of infection would be very low because patients usually start taking these drugs after infection, and the ACE2

future science group

www.futuremedicine.com

1423

Review

Zarkesh, Entezar-Almahdi, Ghasemiyeh et al.

expression would be increased after the infection stage. In this case, it is difficult to say the drug’s direct effect on the
observed large number of receptors. In the early phases of the disease, no specific symptoms are detected in most
patients. However, after the onset of the storm of cytokines, the symptoms of inflammation intensify suddenly and
lead to extensive damage to sensitive tissues such as the lungs. In this case, reducing or even suppressing immune
responses can be helpful [123,124]. In summary, although observations and opinions are different, these drugs must
be utilized with caution when people are infected with SARS-CoV-2 virus.
Naproxen
Naproxen, a member of the NSAID family, reduces fever, pain and inflammation by reducing the mediators
involved in inflammation, such as prostaglandins. Given the current crisis caused by the SARS-CoV-2 virus,
scientists are finding many ways to fight it. One way is to target the viral N-nucleoprotein to prevent it from
binding to the RNA of the virus. This pathway can be an essential strategy to decrease the outbreak of the virus
and any possible role associated with the N-nucleoprotein. Previous studies have shown the beneficial effects of
naproxen on infections caused by the influenza A virus [125,126]. Today, molecular modeling suggests that the drug
binds to N-nucleoprotein. In addition, in laboratory models of SARS-CoV-2-infected cells, naproxen has displayed
inhibitory effect on the replication of the viruses in Vero E6 cells [127]. In general, it is suggested that by binding
the drug to the viral N-nucleoprotein, the connection between viral RNA and this complex protein would be
disrupted, resulting in a reduction in virus replication [5,128]. In general, relying on the lack of scientific evidence of
naproxen’s severe toxicity and the proven effects of this drug on reducing cytokine storm syndrome (CSS), it can
be stated that the use of this drug can reduce the syndromes caused by COVID-19.

Mucolytic agents

Acetylcysteine
This drug is used in the treatment and improvement of some diseases such as cystic fibrosis. Some anti-inflammatory
and anti-cytokine activities via the NF-κB pathway have been suggested for this drug [129].
The reason for focusing on this drug to improve the condition of patients with COVID-19 is the effect of
acetylcysteine on increasing the production of glutathione (GSH). GSH is an intracellular antioxidant substance
that is not able to transport across the membrane. On the other hand, acetylcysteine can easily cross the membrane
and enter the cell from the extracellular environment. When acetylcysteine enters the cell, GSH production
eventually increases, and the cell’s antioxidant power increases during inflammatory diseases [130]. The thickness of
the mucous membrane inside the respiratory tract increases significantly in patients with COVID-19. It has been
observed that molecules with high disulfide reduction capacity, such as acetylcysteine, can reduce disulfide bonds
in the mucosal matrix, thereby reducing the thickness of the mucosal layer. This activity increases with increasing
pH of the environment, and the greatest effect is observed at pH levels between 7 and 9 [131]. Also, in some patients
with COVID-19, glucose-6-phosphate dehydrogenase (G6PD) deficiency has been shown to accelerate disease
progression and intensify the syndromes of the infection. This relationship has led some researchers to consider the
use of acetylcysteine in the treatment of COVID-19. By reducing the intracellular level of G6PD, the reductive
molecules of glutathione are reduced, and as a result, the reducing agents of disulfide bonds within the mucosal
matrix are reduced. These cases ultimately lead to an increase in the thickness of the mucosal layer in patients with
COVID-19 and cause shortness of breath. These difficult cases can be cured with the use of acetylcysteine.
On the other hand, the positive effects observed from the consumption of acetylcysteine in patients may also be
due to the anti-cytokine activity. These cases need to be further studied. Due to the inherent increase in the level
of oxidants in the older body, the risk of death increases in the elderly infected with this virus. Especially in people
over the age of 80 and for males, the risk of death is very high. As mentioned, acetylcysteine can delay this process
by increasing GSH levels in the cells and can greatly help the recovery of older patients from the disease [132]. These
theories are reliable with the detected observations. It has been observed that in patients the effect of normal levels
of antioxidants, and serum levels of GSH molecule, is out of balance [133]. On the other hand, as mentioned earlier,
ACE2 receptors play a vital role in attaching the virus to the surface of the respiratory cells. Thanks to recent
studies, it is known that the amino acid cysteine displays a significant role in the binding of virus S-proteins to
these receptors. As a result, the use of acetylcysteine, which ultimately leads to a reduction in disulfide bonds, is a
good strategy for treating patients with dehydration [130].
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Bromhexine hydrochloride
Bromhexine is extracted from vasicine, an alkaloid and a major component of the plant Justicia adhatoda [134].
Bromhexine, like acetylcysteine, is a drug that helps reduce mucus secretion [135]. Deforming the glycoproteins
in the secretions that cause mucosal adhesions [136], it ultimately reduces this property in the mucosal layer and
facilitates breathing for patients. It has been prescribed since 1963 as a potent cure for diseases such as asthma [137]
and bronchitis [138]. In previous studies, the combined effect of this drug with antibiotics has opened many hopes
for the use of this drug in viral infections [139]. Considering the features mentioned for bromhexine, the hypothesis
of using this drug to improve patients with COVID-19 has been strengthened.
In addition to the ACE2 membrane surface protein, serine proteinase 2 also plays a significant role in viral
attachment to cells. Bromhexine has been shown to be potent in binding to this protein, eventually inhibiting this
receptor and preventing the virus from entering human cells. Because the positive effect of this drug in treating
MERS and SARS has already been observed [140], many efforts have been made to prove its effectiveness in treating
COVID-19 [141]. It is currently used experimentally, about 13% in SARS-CoV-2-infected patients in China. In
summary, due to its very low incidence of side effects, the use of bromhexine hydrochloride is recommended to
improve infectious disease [138].
Immunomodulatory drugs

ARDS could happen during COVID-19 infection. This syndrome can cause hyperinflammation and CSS, leading
to organ failure [142]. The administration of immunomodulatory drugs could be an effective and promising approach
to circumventing these harmful immunological responses [143–145]. Critical immune modulators are discussed below
(Table 3).
Anakinra
Anakinra is an IL-1 receptor antagonist. Anakinra is authorized for use in patients with RA. Moreover, it has also
shown therapeutic benefit for severe sepsis in patients with multi-organ dysfunction [146]. An effective strategy
of targeting IL-1 has been implemented to eliminate the requirement for mechanical ventilation in COVID-19
patients who are not admitted to ICU [111,147]. Thus, a need for a recombinant human IL-1 receptor antagonist
(IL-1Ra) (anakinra) is felt. In a retrospective clinical study, anakinra was administered to non-ICU patients with
COVID-19; the findings suggested that 5 mg/kg twice a day intravenously is safe and enhanced the clinical
outcomes in 72% of patients [148,149]. In another cohort study, anakinra was co-administered in ICU patients who
were also placed on mechanical ventilation. Anakinra decreased the requirement for mechanical ventilation and the
mortality rate due to ARDS [146].
Interferon-alpha & interferon-beta

IFN-α and IFN-β have shown both antiviral and immunomodulatory effects [150]. These classes of IFNs have a
direct effect on viral particle replication, protein synthesis and release from infected host cells. Moreover, IFN I
enhances macrophage activity [151–153]. As a consequence, IFN I is administered in HBV and HCV [154,155], multiple
sclerosis [156] and some types of malignancies such as hairy cell leukemia, melanoma and lymphoma [157–159]. Among
the various isoforms of IFN-α and β, IFN-α-2b and IFN-β-1a are the most studied IFNs in COVID-19 [38]. A
clinical trial was conducted on patients who were admitted to the Hong Kong hospitals [160]. Their treatments were
LPV 400 mg twice a day (b.i.d.)/ritonavir 100 mg b.i.d./ribavirin 400 mg b.i.d./IFN-β-1b 8 million units (three
doses), compared with patients treated without IFN for 14 days. This study indicated that the group receiving
combination therapy with IFN had a significantly reduced duration to a negative swab test [160]. Therefore,
administration of IFN with other antiviral drugs was effective in earlier viral clearance. In a single-arm prospective
clinical trial, patients received IFN-β-1a 44 μg s.c. (five doses for 10 days) beside HCQ and LPV/ritonavir. This
study indicated that administration of IFN also significantly reduced the time of viral clearance and recovery of
patients [152].
Corticosteroids
There is much controversy in the literature regarding the advantageous effects of corticosteroids in dealing with
COVID-19. From the pathophysiological perspective, after SARS-CoV-2 virus enters the host cells, the innate
immune system is the initial responder. Unless the inflammatory response is regulated, CSS can occur [161]. CSS
induces clotting, hyperinflammation, thromboembolismand ultimately hypovolemic shock [162]. It seems that
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Table 3. Classification of possible COVID-19 treatment in the following categories: immunomodulators,
corticosteroids, immunosuppressants and anticoagulants.
Drug

Administration

Mechanism of action

Contraindication

Major side effects

Anakinra

5 mg/kg twice a day iv.or
100 mg twice a day sc.

IL-1 receptor antagonist

Hypersensitivity to anakinra
and E. coli isolated proteins

Injection site reaction, headache

[148]

Ref.

IFN-1

44 μ g sc. (five doses for
10 days)

Inhibits viral replication, virus
maturation and release from
infected cells; improves
macrophages, T cells and NK
cell activity

Hypersensitivity, autoimmune
hepatitis, decompensated
liver disease

Fever, neutropenia flu-like
syndrome, fatigue

[152]

(Methyl)prednisolone

40 mg once or twice daily

Avoids or controls (hyper)
inflammation and CSS

Most of the virus vaccines,
untreated serious infections

Edema, acne, adrenal
suppression

[182]

Dexamethasone

6 mg orally or iv. daily

Anti-inflammatory to inhibit
CSS

Hypersensitivity

Edema, hypertension,
hyperglycemia

[204]

Hydrocortisone

100 mg by iv. bolus injection
followed by 50 mg iv. every
6 h or 200 mg/day by
continuous iv. infusion

Anti-inflammatory

Untreated serious infections,
hypersensitivity

Adrenal suppression

[173]

Budesonide +
formoterol

Continue the administered
dose for controlling asthma
or COPD

Anti-inflammatorybronchodilator

Hypersensitivity

Upper respiratory tract infection

[180]

Fingolimod

0.5 mg orally once per day,
for 3 days

Sphingosine-1-phosphate
receptor regulator

Hypersensitivity, within past
6 months of MI, stroke or
angina

Liver enzyme elevations (ALT and
AST)

[182]

Leflunomide

50 mg twice daily, three
consecutive times, after
20 mg, once daily, for 10 days

DHODH inhibitor, immune
regulator

Pregnancy, hypersensitivity,
severe liver damage

Elevation of the levels of liver
enzyme, ALT and AST

[184]

Thalidomide

100 mg by mouth once daily

Suppresses TNF-␣, IL-6

Hypersensitivity, teratogenic
drug even in a single dose in
pregnant women

Embryo-fetal toxicity

[187,188]

Tocilizumab

400 mg iv. once daily or
Monoclonal antibody against
8 mg/kg iv. up to 800 mg daily IL-6

Hypersensitivity

Increased risk of severe infections
(e.g., tuberculosis),
hypersensitivity, erythema,
pruritis

[192,196]

Sarilumab

400 mg iv. once daily

Monoclonal antibody against
IL-6

Hypersensitivity to sarilumab
or excipients

Increased risk of severe infections
(e.g., tuberculosis),
hypersensitivity, erythema,
pruritis, elevated liver enzymes
(ALT and AST)

[200]

Adalimumab

40 mg sc. every other week

Recombinant human TNF-␣
immunoglobulin G (IgG)1
monoclonal antibody

-

Upper respiratory tract infection

[205]

Bevacizumab

7.5 mg/kg + 0.9% sodium
chloride 100 ml, iv. drip

Recombinant humanized
anti-VEGF monoclonal
antibody

-

Fatigue, nausea

[207]

Ravulizumab

Day 1: (2400 mg for
≥40–⬍60 kg, 2700 mg for
60–100 kg, 3000 mg for
≥100 kg); days 5 and 10:
(600 mg for ≥40–⬍60 kg or
900 mg for⬎ 60 kg); day 15:
(900 mg)

Recombinant monoclonal
antibody that inhibits
complement pathway

Neisseria meningitidis
infection and patients who
are not vaccinated for
Neisseria meningitidis

Upper respiratory tract infection

[214]

Lenzilumab

600 mg 1-h iv. infusion every
8 h for three doses

Recombinant monoclonal
antibody that neutralizes
GM-CSF

-

-

[218]

LMW heparin or
enoxaparin sodium

40 mg once per day or 40 mg
twice per day

Inhibition of factor Xa,
antithrombotic agents

Active major bleeding,
heparin-induced
thrombocytopenia

Hemorrhage

Rivaroxaban

20 mg once daily

Inhibition of factor Xa,
platelet activation

Hypersensitivity, active
pathological bleeding

Hematoma

[232,233]

[231]

CSS: Cytokine storm syndrome; COPD: Chronic obstructive pulmonary disease; DHODH: Dihydroorotate dehydrogenase; GM-CSF: Granulocyte-macrophage colony-stimulating factor;
LMW: Low molecular weight; NK cells: Natural killer cells.
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avoiding these conditions by using corticosteroids is of interest. Still, it should be considered that inflammation
is the result of immune activation, and suppressing the entire immune response may cause the relapse of viral
replication and reduce viral clearance. Therefore, keeping a balance between immune response and viral replication
and infection should be considered (Table 3) [39].
Methylprednisolone
Methylprednisolone is an anti-inflammatory drug that interacts with specific cytoplasmic receptors and regulates
protein synthesis. Methylprednisolone inhibits the phospholipase A2 protein, which plays a major role in synthesizing inflammatory mediators such as prostaglandins and leukotrienes [163]. In an observational study, 40 mg of
methylprednisolone administered once or twice daily was evaluated [164]. Results indicated that there was no clinical
benefit in the treatment arm receiving methylprednisolone. Methylprednisolone did not influence the duration of
hospitalization, virus clearance and duration of symptoms [164].
Dexamethasone
Dexamethasone is another corticosteroid with antiemetic properties. Dexamethasone is an agonist for the glucocorticoid receptor (GR) [165]. Its anti-inflammatory effect can control severe allergic symptoms. Therefore, it can
be a remedy for asthma, atopic and contact dermatitis, seasonal allergic rhinitis and other disorders related to
adrenocortical steroids.
Because this corticosteroid has a prolonged clearance rate, broad-spectrum effects can take place on the innate
and adaptive immune systems and can suppress the cytokines’ destructive function [166–168]. In a case–control
clinical trial for COVID-19, hospitalized patients received 6 mg dexamethasone p.o. or iv. daily for 10 days [169].
Dexamethasone treatment for patients under mechanical ventilation or oxygen demonstrated clinical benefits and
an improved mortality rate. However, dexamethasone did not show clinical beneficial effects in patients not using
ventilators [169].
Hydrocortisone
Hydrocortisone is a corticosteroid that interacts with both glucocorticoid and mineralocorticoid receptors. Some
reports indicate that hydrocortisone can inhibit oxidative metabolism, although it has lower anti-inflammatory
properties than prednisolone and dexamethasone [170]. Hydrocortisone would be a suitable replacement for those
who suffer from cortisol deficiency. It is used to treat a vast range of inflammatory diseases, such as anaphylaxis,
angioedema and adrenal crisis. Several methods of administration are used, such as oral, intravenous injection, and
topical application [171].
For hospitalized patients suffering from critical conditions such as ARDS and exacerbating conditions, higher
doses of corticosteroids are administered. For example, a study suggested that hydrocortisone 50–100 mg as bolus
administration and then infusion of 200 mg/day was a suitable regimen for adrenal-insufficient patients with
sepsis [172]. Adrenal crisis is a serious cause of death, and once adrenal crisis occurs in COVID-19 patients, the dose
of hydrocortisone should be doubled [173].
Budesonide/formoterol combination
R
) is a corticosteroid and beta-2 (β2 ) adrenergic agonist.
Budesonide/formoterol combined preparation (Symbicort
Budesonide/formoterol is another anti-inflammatory agent and bronchodilator [174]. Inhaled corticosteroids (ICSs)
alone or with long-acting β2 agonist as a bronchodilator such as budesonide + formoterol was previously used for
the management of asthma and chronic obstructive pulmonary disease (COPD) [175,176].
Often, the early signs of COVID-19 are cough and fever. After 8 days, the onset of dyspnea occurs in 20% of
patients and is followed by ARDS in hospitalized patients [177]. There is some controversy regarding the use of ICSs
in the management of COVID-19 due to some reports of exacerbated effects on viral respiratory infections [178,179].
However, it is suggested that patients who have eosinophilic asthma or COPD continue their ICS therapy to reduce
symptoms and protect them from viral triggers such as COVID-19 [180].

Immunosuppressants

Fingolimod
Fingolimod is an immunomodulatory drug. It is an analog of sphingosine, which is phosphorylated by sphingosine
kinase; it regulates sphingosine 1 phosphate receptor. Fingolimod can influence the aggregation and distribution of
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lymphocytes. It isolates and captures lymphocytes in the lymph nodes to prevent their contribution to autoimmune
diseases [181]. Fingolimod is involved in the treatment of inflammatory diseases of the CNS. Presently, fingolimod is
in Phase II of a clinical trial (NCT04280588) for pneumonia caused by COVID-19. In this nonrandomized trial,
fingolimod 0.5 mg was given to patients for 3 days and the change of pneumonia severity on x-ray images was
evaluated after 5 days of treatment [182]. Studies are still under way.
Leflunomide
Leflunomide is considered for autoimmune disorders, mainly influencing joints. Leflunomide inhibits dihydroorotate dehydrogenase (DHODH) and has a critical role in the synthesis of uridine monophosphate (rUMP), which
is vital for DNA and RNA synthesis. This inhibition activates a series of steps that eventually lead to G1-phase cell
cycle arrest [183]. It has FDA approval for curing RA and psoriatic arthritis (PsA). Additional clinical studies have
been performed on a wide range of other diseases such as Felty’s syndrome, Kimura’s disease, SLE and Takayasu
arteritis.
In one study, leflunomide was evaluated in COVID-19 patients [184]. It was indicated that the patients who
received leflunomide had a shorter duration of viral shedding and hospitalization. Moreover, a lower incidence of
inflammatory actions and CSS was observed in comparison with those who did not receive leflunomide [184].
Thalidomide
Thalidomide is an immunomodulatory drug that inhibits angiogenesis. Nowadays, this drug is prescribed for its
anti-inflammatory properties in cancer comorbidities, including multiple myeloma leprosy and graft-versus-host
disease. Moreover, thalidomide significantly reduces oxidative stress and TNF-α, IL-1 and IL-6 production [185–187].
One study showed that thalidomide is a good candidate for preventing lung injury during H1N1 influenza infection,
as shown by a dampened inflammatory response and prolonged survival in mice [188]. Recently, thalidomide has
also been administered in COVID-19 patients for anxiety and nausea. In this way, oxygen consumption is reduced
and digestive symptoms are alleviated [189].
Monoclonal antibodies

As mentioned before, COVID-19 affects several organs, particularly the lungs undergo damage by inflammation and
a cytokine storm [111]. Monoclonal antibodies (mABs) would be used to directly bind to the pivotal inflammatory
cytokines, prevent an immune response and inhibit organ damage. Some of these mABs are listed in Table 3.
Tocilizumab
This drug is a recombinant humanized mAB IL-6 inhibitor. It binds to the IL-6 receptor and dampens its
inflammatory properties [190]. In 2010, the FDA approved the use of tocilizumab for RA and cytokine release
syndrome (CRS) caused by chimeric antigen receptor (CAR) T-cells [191]. Some clinical trials on tocilizumab
proposed this drug as a promising option in alleviating symptoms in COVID-19 patients [192,193]. COVID-19
patients have higher levels of plasma cytokines,interleukin family (IL-2, IL-6, IL-7, IL-10) and are at high risk for
CSS [194]. As depicted in Figure 3, in CRS, IL-6 binds to IL-6R to form a complex that binds to transmembrane
glycoprotein 130 (gp130) for subsequent signal transduction and gene expression. The synthesis of acute reactive
protein is completed through two signaling pathways. Tocilizumab can prevent CSS by inhibiting active complexes
to IL-6Rs [195].
Also, a study on severely ill COVID-19 patients demonstrated that the administration of tocilizumab remarkably
reduced fever within a few days and limited the need for oxygen supplementation [196]. However, administration
of tocilizumab in COVID-19 patients requires more monitoring and further clinical trials in a larger population
to confirm its safety and efficacy [197,198].
Sarilumab
Sarilumab is a human monoclonal antibody that is an IL-6 receptor antagonist; it is approved to treat RA in patients
with severe or critical COVID-19 [199]. Sarilumab inhibits the binding of IL-6 to its α receptor and is mainly used
to treat RA in those who could not tolerate conventional therapies or who have had insufficient feedback to one or
more disease-modifying antirheumatic therapeutics [199].
Considering the major role of IL-6 in the pathophysiology of COVID-19, sarilumab as another mAB against
IL-6 was suggested to alleviate respiratory symptoms [200]. The level of IL-6 in the serum of patients is excessively
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Figure 3. Mechanistic role of tocilizumab in treating COVID-19. Tocilizumab calm inflammatory storm by binding
with the receptor of IL-6 (gp130) and reducing its inflammatory properties in the body [195].

increased and results in an exaggerated immune response. So, the administration of sarilumab may be promising in
the COVID-19 pandemic. However, careful monitoring of its safety and efficacy, due to some adverse effects such
as an indication of severe infections and hypersensitivity, would be considered during and after treatment [201].
Adalimumab
Adalimumab is a TNF-α inhibitor that has more advantages than other TNF-α inhibitors due to its large antigen
size, which increases the binding affinity to tumor necrosis factor receptor (TNFRS) [202]. TNF-α plays a crucial
role in the majority of severe inflammatory mechanisms in the body. It is currently used to treat diseases such as
RA, juvenile idiopathic arthritis (JIA), PsA and ankylosing spondylitis (AS).
COVID-19 patients have higher circulating levels of TNF-α in the plasma and tissues [203]. Therefore, the
administration of anti-TNF-α, such as adalimumab, would be beneficial for COVID-19 patients. However, antiTNF-α therapy presents an increased risk for severe infections [204]. In one study, a 30-year-old patient with a
history of Crohn’s disease was hospitalized with fever and chest pain and tested positive for COVID-19 [205]. He
was already under treatment with 3 g mesalazine daily and 40 mg s.c. of adalimumab every other week. Interestingly,
his fever and chest pain resolved after 24 h and he became asymptomatic on the fifth day. It was suggested that
the administration of adalimumab might have been beneficial in this case, owing to suppression of the immune
system [205].
Bevacizumab
Bevacizumab is a humanized mAB that targets VEGF. VEGF is known to be elevated during the hyperinflammation
stage and is upregulated in infected respiratory tract epithelial cells [206]. VEGF promotes vasculogenesis and
angiogenesis [207] and has an important role in ARDS outcomes [208]. Inhibition of VEGF influences tumors
through several mechanisms; it prevents the growth of other vessels and improves the normal function of vessels [209].
Bevacizumab is approved for renal cell carcinoma, colorectal cancer and metastatic breast cancer [207]. Bevacizumab
is used in the early stages of treatment when it has not yet been transmitted to other parts of the body. Bevacizumab
is not used after surgery. Some trials are currently assessing the safety and efficacy of this mAB in COVID-19
treatment. For example, a randomized, double-blind clinical trial suggested that bevacizumab with other standard
care was very effective by enhancing oxygenation and decreasing the duration of oxygen usage [207].
Ravulizumab
Ravulizumab is a recombinant mAB that attaches to the complement protein C5 with high affinity and inhibits
the production of terminal complement complexes while playing a critical role in the immune system. When C5 is
blocked, immune system responsiveness is reduced. Ravulizumab is used to treat adults with paroxysmal nocturnal
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hemoglobin (PNH) [210]. Recently, ravulizumab was considered as a suitable substitute for eculizumab in PNH
patients.
Some reports indicate that in severe COVID-19 cases, some vital molecules of the complement system, such as
C3a and C5a, are activated. This complement activation leads to systemic thrombotic microangiopathy (TMA)
and multi-organ damage [211,212]. In this circumstance, a complement system inhibitor might be helpful. A clinical
trial has been conducted to evaluate the safety and efficacy of ravulizumab in the management of COVID-19
patients with severe pneumonia [213,214].
Lenzilumab
Lenzilumab is a recombinant mAB against granulocyte macrophage colony-stimulating factor (GM-CSF). GMCSF has a critical role as an initiator in inflammatory reactions [215]. Lenzilumab is in Phase III study for COVID-19.
Due to the critical role of GM-CSF in pulmonary homeostasis and inflammation, there is a concern to block the
receptor of GM-CSF or inhibit GM-CSF signaling in COVID-19 patients [216]. GM-CSF receptor blockade would
be advantageous to prevent CSS and inflammatory myeloid cell tissue infiltration induced by COVID-19 [217]. In
this regard, a cohort study was conducted to evaluate the safety and efficacy of lenzilumab with a dose of 600 mg
iv. for three doses in COVID-19 patients with severe pneumonia. The study suggested that lenzilumab is safe and
enhanced the clinical outcomes in hospitalized patients [218].
Anticoagulants

Systemic inflammatory responses, including the activation of innate immunity by viral infections, lead to activation of coagulation and thrombin pathways called ‘immuno-thrombosis’ [219]. The complement system can
activate coagulation factors, and CSS can cause activated vascular endothelial cell damage with prothrombotic
characteristics [220,221]. Thus, the use of anticoagulants can reduce the risk of thrombosis in COVID-19 patients
(Table 3) [222].
Low molecular weight heparin
Low molecular weight heparin (LMWH), or enoxaparin sodium, is an anticoagulant therapy. LMWH activates
antithrombin (AT), which in turn inactivates enzymes involved in coagulation. It is used to treat deep vein
thrombosis (DVT) and ST-segment elevation myocardial infarction (STEMI) [223].
There are some reports of DVT in hospitalized COVID-19 patients. Although the administration of LMWH
would be beneficial for COVID-19 patients with coagulopathy [224–226], identifying the optimal therapeutic window
is essential [227]. According to the literature, heparin can also diminish myocardial inflammation and remodeling by
decreased collagen deposition in vivo [228]. Thus, this cardiac improvement would be advantageous in COVID-19
patients [227]. Moreover, heparin can influence microcirculation and prevent organ damage [229].
Rivaroxaban
Rivaroxaban is another anticoagulant. It was the first oral medication that exerts its effects through the direct
inhibition of thrombin or factor Xa . It is a derivative of oxazoline and exerts its pharmacological effect by binding
to factor Xa [230]. It is used for atrial fibrillation, DVT and pulmonary embolism (PE) [208].
A 79-year-old patient, hospitalized for COVID-19 pneumonia, experienced an episode of acute PE 4 weeks after
discharge [231]. However, the patient was receiving rivaroxaban with sufficient drug plasma levels. This case showed
concern about rivaroxaban effectiveness in COVID-19. It is recommended that rivaroxaban could be replaced with
LMWH until the complete remission of illness [231].
Cardioprotective agents

Aspirin
Aspirin (acetylsalicylic acid [ASA]) is authorized for use in various illnesses such as angina pectoris, colorectal cancer,
osteoarthritis and SLE [234]. Aspirin is an inhibitor of cyclooxygenase 1 (COX-1) and a modifier of COX-2 activity.
Unlike other NSAIDs, which reversibly inhibit this enzyme, aspirin binds to COX-2 irreversibly. On the other
hand, it irreversibly blocks thromboxane A2 on platelets, preventing platelet aggregation [89].
Aspirin is not ordinarily recommended in the guidelines of COVID-19 treatment. However, it has been confirmed
to exhibit antiviral effects by inhibiting prostaglandin E2 (PGE2) in macrophages and upregulate type I IFN, and
inhibit virus replication [235]. Under certain circumstances, platelets contribute to innate immune responses. Previous
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studies indicate that aspirin and antithrombotic drugs could reduce dynamic neutrophil and platelet aggregation
in an animal model of lung injury [236]. Among the major complications in patients diagnosed with COVID-19 is
the risk for acute lung injury (ALI) and ARDS [237]. Evidence suggests a relationship between taking aspirin prior
to hospitalization and ALI/ARDS [238]. A report by Kor et al. also showed that 25% of the 3855 patients who
received aspirin scored higher on an acute physiologic and chronic health evaluation and had a lower incidence of
ALI/ARDS [239]. A study by O’Neal et al. suggested that patients who took aspirin and statins before hospitalization
had the lowest mortality rates from ALI/ARDS [240].
Atorvastatin
Atorvastatin is an FDA-approved lipid-lowering agent. When combined with dietary modifications, it lowers the risk
of cardiovascular events in individuals with cardiac risk factors and abnormal lipid profiles [241]. Atorvastatin hinders
β-hydroxy β-methylglutaryl-coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme converting 3-hydroxy-3methylglutaryl coenzyme A to mevalonate, a precursor of various sterols, including cholesterol [92,242]; furthermore,
“atorvastatin is contraindicated in active liver disease” [92], unexplained persistent incline of liver transaminase levels,
pregnancy and nursing mothers. By interacting with Toll-like receptors on the host cell membrane, COVID-19
increases the expression of the MYD88 gene and eventually activates NF-κB to activate the inflammatory cascade.
Statins have been shown to stabilize MYD88 expression levels after a pro-inflammatory trigger and significantly
attenuate NF-κB activation [243]. The schematic mechanism of statins in the management of COVID-19 is shown
in Figure 4. Reduced risk of death due to influenza among statin users has been reported [244].
Clopidogrel
Clopidogrel is an anticoagulant drug that is used to lessen ‘the rate of stroke in patients with non-ST-segment
elevation, acute coronary syndrome’ (ACS), acute ‘ST-elevation MI, and unstable angina/non-ST-elevation MI’ [245].
Clopidogrel is sometimes administered in combination with ASA [246]. Clopidogrel is a prodrug that is absorbed in
the intestine and is converted to thiol-containing active metabolites that are able to inhibit platelet aggregation. The
active metabolites of clopidogrel irreversibly and selectively hinder the ‘binding of adenosine diphosphate (ADP) to
P2Y12 receptor’ on platelets and ‘ADP mediated activation of the glycoprotein IIb/IIIa complex’, thus inhibiting
the aggregation of platelets [247]. Several agents used in the treatment of COVID-19 interact with oral antiplatelet
agents. It has been reported that LPV/ritonavir, a protease inhibitor that hinders cytochrome P450 3A4 (CYP3A4)
metabolism, may lead to decreased serum concentration and affect clopidogrel pharmacokinetic properties [248,249].
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Patients with COVID-19 may experience hypoxia, endothelial dysfunction and alveolar involvement, which
in turn cause micro-pulmonary thrombosis. The effect of antiplatelet therapy on arterial oxygenation in patients
was assessed in a clinical setting [250]. Antiplatelet therapy is effective in improving the partial pressure of arterial
oxygen (mmHg) PaO2 /fractional inspired oxygen (FiO2 ) ratio in patients by preventing the formation of clots in
the capillaries of the lung and improving the function of megakaryocytes and platelet adhesion. Inhibition and
modulation of COX by clopidogrel in platelets as well as megakaryocytes can prevent the formation of thrombosis
and increase the level of PaO2 [250].
Tyrosine kinase inhibitors

Imatinib
Imatinib is a bcr-abl tyrosine kinase inhibitor. Imatinib also inhibits tyrosine kinase receptors involved in the
function of stem cell factor (SCF), PDGF and c-kit and in turn inhibits PDGF- and SCF-mediated cellular
action [251].
Imatinib is a curative therapy prescribed to adolescent patients with chronic myeloid leukemia ‘Philadelphia chromosome-positive’ in blast crisis, in accelerated phase, and in chronic phase following failure of IFN-α
treatment [252]. It is also used in patients with recurrent disease after stem cell transplantation and individuals
who do not respond to IFN treatment [253]. Besides the conventional mechanism of action, imatinib also exhibits immunomodulatory properties that assist in COVID-19 management. Considering hyperinflammation in
COVID-19, the role of imatinib in modulating host immune response is noteworthy. Imatinib exhibits antiviral
properties in vitro against two viruses phylogenetically related to SARS-CoV-2, SARS and MERS. In this sense,
Abelson kinases type 2 (ABL2) seem to be involved in the virus–cell fusion process. Inhibition of ABL2 could
control viral entry into the host cells. Imatinib also inhibits c-KIT and PDGF receptors. Imatinib has been shown to
prevent lung injury in animal models of COVID-19 by reducing pulmonary edema, it prevents histological damage
and it improves endothelial barrier dysfunction. This phenomenon is likely mediated by reducing pro-inflammatory
cytokine release such as IL-6 and TNF-α. These effects could be implemented by inhibiting transcription factor
NF-κB based on recent in vivo and in vitro evidence [254,255].
Acalabrutinib
Acalabrutinib is the inhibitor of Bruton tyrosine kinase (BTK). Acalabrutinib – and its active metabolite, ACP-5862
–bind to the active site of BTK, leading to the inhibition of BTK. BTK signaling triggers B-cell proliferation [256].
This drug could also inhibit the activation of downstream signaling molecules of BTK, such as CD86 and CD69,
impairing the expansion and survival of malignant B-cells [257].
Acalabrutinib is used to treat patients who are diagnosed with mantle cell lymphoma. Serious and opportunistic
infections, hemorrhage and cytopenia are among the significant side effects of this drug [258]. A study on patients
who were treated with acalabrutinib for 10–14 days revealed that the levels of IL-6 in serum decreased following
treatment. By the end of the treatment, 73% and 25% of patients that were on supplemental oxygen or mechanical
ventilation, respectively, were discharged on room air [259]. Considering the role of acalabrutinib in COVID-19
treatment, when a macrophage ingests a viral particle, it triggers a signaling pathway that proceeds through BTK [260].
Treatment with BTK inhibitors in patients with leukemia has been very effective and shows a good safety profile,
even among patients who are on treatment for years. The hypothesis is that by inhibiting BTK, the inflammatory
balance within the lungs is improved and CSS is prevented, and ultimately patients can breathe better. Although
this complication is uncommon, BTK inhibitors, such as acalabrutinib, might help control macrophage-dominated
inflammatory responses.
Blood samples collected from COVID-19 patients showed that BTK was active in all [261]. In a clinical study on
a small group of hospitalized patients, acalabrutinib was administered. Within 10–14 days of therapy, their oxygen
supply and inflammatory factors, such as CRP and IL-6, improved significantly [260]. The effects of acalabrutinib
are evident in patients receiving supplemental oxygen, such as mechanical ventilation. Half of the patients who
used the mechanical ventilation died after receiving acalabrutinib. In this study, no side effects were observed in
the long-term use of acalabrutinib, advocating its beneficial effects in COVID-19 [260].
Fedratinib
Fedratinib is a tyrosine kinase inhibitor acting on Janus-associated kinase 2 (JAK2) and FMS-like tyrosine kinase 3
(FLT3) [262]. Fedratinib is indicated in the management of patients with myeloproliferative diseases [263]. Fedratinib
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suppresses the production of several cytokines, preventing CSS in COVID-19 patients. Fedratinib is also prescribed
in combination with other antiviral drugs [264].
Serotherapy

Convalescent plasma transfusion
Since the 20th century, convalescent plasma transfusion has been recognized as an alternative therapeutic plan
of action in preventing and managing several infectious diseases and is thought to induce passive immunization.
Convalescent plasma is drawn from a patient who has recently survived an infectious disease and whose plasma is
rich in antibodies that can help another person who is suffering from the same infectious disease. It has been reported
that early administration of convalescent plasma therapy remarkably lowered the mortality rate in respiratory viral
infectious diseases during previous pandemics, including HINI influenza, SARS and MERS [265]. Convalescent
plasma contains defensins, clotting factors, anti-inflammatory cytokines, neutralizing antibodies and other proteins
that can induce immunomodulatory responses and avoid the CSS and ARDS complications common in SARSCoV-2 infection. This therapeutic approach is safe and does not exhibit significant drug interaction complications,
especially in patients with underlying diseases [4,265]. Apheresis is the recommended method of plasma acquisition
from recovered donors. Pre-donation assessments, such as ABO-compatibility, are essential to prevent unwanted
reactions. Neutralizing antibodies in convalescent plasma are beneficial in SARS-CoV-2 clearance and induction
of passive immunity. Also, non-neutralizing antibodies in convalescent plasma, such as IgM and IgG, could induce
protective and/or therapeutic effects against COVID-19. Therefore, convalescent plasma transfusion would be
considered a safe therapeutic or prophylactic agent against SARS-CoV-2 [265].
Although the volume of plasma transfusion and neutralizing antibody titers are variable, there is no correlation
between these parameters and clinical response [266]. The recommended amount of convalescent plasma transfusion
proposed is 200 (ml) with a 1:640 ratio neutralizing antibody titers. Still, more clinical trials should be implemented
to validate these values. Outcomes of a recent study indicated that convalescent plasma transfusion in severe cases
(COVID-19) was significantly linked with improving oxyhemoglobin saturation within 3 days of hospitalization.
Also, lymphocyte count was significantly enhanced, and CRP was reduced after convalescent plasma transfusion.
This study on plasma transfusion in severe cases of COVID-19 reported no significant adverse reaction related to
convalescent plasma transfusion. A recent randomized clinical trial study on hospitalized patients conducted in the
Netherlands compared the efficacy of convalescent plasma transfusion (300 ml with neutralizing antibody titers of
at least 1:80 ratio) with the standard of care therapy [267]. This study revealed no statistically significant difference
in regard to mortality rate, disease severity and length of hospital stay between those who received convalescent
plasma and the control arm that received standard therapy [267]. The results of a case series study on the efficacy
of convalescent plasma transfusion in a hospitalized Swedish population who were severely ill due to COVID-19
infection revealed that although laboratory and inspiratory data, such as CRP and PaO2 /FiO2 ratio, were improved
in the convalescent plasma group, the clinical status was the same in both treatment groups [268]. However, this study
suffers from a small sample size and short-term patient follow-up. The results of this study emphasized the safety of a
convalescent plasma infusion, with no adverse reactions after ABO-compatibility confirmation [268]. The incidence
of venous thromboembolism was high in both case and control groups, but it was not higher in the convalescent
plasma therapy group [268]. Finally, in August 2020, the FDA confirmed emergency use authorization (EUA) of
convalescent plasma therapy to manage critically ill COVID-19 hospitalized patients. The FDA emphasized that
plasma should be obtained from COVID-19 recovered patients who did not have clinically relevant symptoms
for the last 10 days and who had laboratory-confirmed negative SARS-CoV-2 tests. Plasma has FDA approval for
a ‘serious or immediately life-threatening COVID-19’ infection [269].
Intravenous immunoglobulin
Since the most effective therapeutic agents in COVID-19 management have emerged from the immunomodulation
basis, the administration of intravenous immunoglobulin (IVIG) would be a promising strategy. IVIG is a liquid
human immunoglobulin that contains polyclonal IgG antibodies [270]. IVIG had been introduced as an efficient
agent in many viral and bacterial infections, inflammatory diseases and autoimmune diseases. IVIG could act as
an immunomodulator through the inhibition of pro-inflammatory cytokines. IVIG immediately enhances blood
IgG levels that can neutralize SARS-CoV-2 exogenous antigens. Also, it can enhance circulating lymphocytes and
innate immune cells. Because there is a lack of selective antibodies in the treatment of the new SARS-CoV-2,
the efficacy of IVIG administration in COVID-19 is still controversial [270]. It has been hypothesized that IVIG

future science group

www.futuremedicine.com

1433

Review

Zarkesh, Entezar-Almahdi, Ghasemiyeh et al.

administration in combination with dexamethasone and IFN-ß could be beneficial for COVID-19 patients who
have progressed to ARDS [271]. A report of a multi-center retrospective cohort study on assessment of IVIG efficacy
in COVID-19 management revealed that early administration (<7 days of hospital admission) of a high dose of
IVIG (>15 g/day) resulted in reduced 60-day fatality in critically ill patients [270]. A serial case study on patients
showed that administration of high-dose IVIG (with a dosage of 0.3–0.5 g/kg/day for 5 days) in the early stages
of COVID-19 disease was significantly associated with the blockage of disease progression and improvement in
clinical outcome [272]. It has been reported that high-dose IVIG would be a promising immunomodulatory therapy
in prophylaxis and management of inflammatory and infectious diseases, particularly in immune-compromised
patients. However, further larger, randomized, controlled trials are needed to support the efficacy and safety of
IVIG therapy at different stages of COVID-19 disease.
Other treatments

Vitamin C
Ascorbic acid, also known as vitamin C, is an antioxidant agent that is a potential scavenger of the harmful reactive
oxygen species (ROS) and prevents oxidative stress damage to cells and tissues. Vitamin C also plays a role as an
essential supporter of a healthy immune system [273]. Vitamin C can inhibit NF-κB, a crucial factor in immune
defense activity, by regulating the production of cytokines, chemokines and inflammatory mediators [274,275]. Also,
the action of vitamin C in the inhibition of IL-6 and TNF-α is significant in terms of inflammatory and infectious
disease management. Vitamin C can regulate the production of T lymphocytes, B lymphocytes and natural killer
NK cells and can decrease the signaling responses of GM-CSF. According to the aforementioned mechanisms,
vitamin C could be a promising agent in managing CSS [275,276]. During viral or bacterial infections, the level of
vitamin C is diminished, and the amount of this reduction is correlated with the severity of the infectious disease. A
high-dose intravenous injection of vitamin C may be beneficial in severe infections. Also, there are some suggestion
of the direct viricidal effect of vitamin C [276]. A recent study indicated that a high intravenous dose of vitamin C
(15 g/day for 4 days) in patients with severe cases of COVID-19 who progressed to ARDS could reduce the mortality
rate [274]. Since oxidative stress has a crucial role in the pathophysiology of COVID-19, vitamin C administration,
as an antioxidant agent, can prevent oxidative damage to the bronchial epithelium and further ROS-induced lung
damage. It could also be beneficial in the management of COVID-19-induced ARDS and respiratory failure. A
recently published meta-analysis showed that high-dose intravenous administration of vitamin C could reduce the
length of hospitalization, the duration of mechanical ventilation requirements [276] and ICU mortality rates [277].
Also, it has been reported that high-dose intravenous administration of vitamin C (200 mg/kg) could reduce the
incidence and score of multi-organ failure (MOF) in critically ill COVID-19 patients with sepsis or ARDS. Some
reports claim that high-dose intravenous vitamin C administration (10–20 g/day infusion over 8–10 h) in the
Chinese population with COVID-19 could enhance the oxygenation index [277]. A multi-center, randomized clinical
trial on COVID-19 patients evaluating the safety and efficacy of high-dose intravenous vitamin C administration
started in February 2020. Results of this study would be helpful to support the efficacy and safety [275]. Since vitamin
C is a safe and inexpensive nutritional agent, consideration of vitamin C administration during the COVID-19
pandemic would be promising [276]. Administration of intravenous vitamin C with doses of up to 1.5 g/kg/day
would be considered safe with no severe adverse drug reactions (ADRs) [277].
Deferoxamine
It is suggested that SARS-CoV-2 can damage hemoglobin molecules. New SARS-CoV-2 can damage the beta
chain of hemoglobin, resulting in the separation of iron from the heme molecule. Hence, iron overload would be a
common consequence of SARS-CoV-2 infection. Recent reports show many COVID-19 patients had high serum
ferritin values [278]. The released iron can be converted to porphyrin, which might progress to hypoxemia. Due
to disturbance in oxygen delivery, MOF would be expected in these COVID-19 patients [273]. Iron overload and
iron toxicity have multi-stage consequences. The first stage is GI events such as nausea/vomiting and diarrhea, the
second stage is the apparent recovery of the first-stage symptoms and the third stage is metabolic acidosis, septic
shock, ARDS and MOF. The latest stage of iron overload would be hepatic failure and elevation in the levels of
aminotransferase. Since these symptoms are common in severe COVID-19 cases, the management of iron overload
using an iron chelating agent, such as deferoxamine, would be beneficial in these patients. It has been suggested that
iron level assessments in these patients would be helpful in the initiation of deferoxamine therapy. If the serum iron
level passes over 500 μg/dl in hospitalized COVID-19 patients, deferoxamine can be prescribed, with a loading
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dose of 1000 mg and followed by 500 mg q4h for two other doses. In some patients, doses might be enhanced
up to 6 g/day [279]. Also, some evidence shows that the iron overload process could enhance viral replication and
disease severity. It has been suggested that iron chelating agents could be beneficial in preventing lung injury and
lung fibrosis in patients through the reduction of viral replication. Also, it has been suggested that deferoxamine
could have synergistic effects with antiviral agents, such as remdesivir, in reducing the viral replication cycle.
Another possible mechanism of deferoxamine in decreasing the COVID-19 severity course would be through reducing IL-6 values and diminished endothelial inflammation, which could prevent COVID-19-induced MOF [278].
Hyperferritinemic syndrome has clinical, laboratory and atopic similarities to COVID-19 pneumonia, including
lymphopenia, coagulopathy, enhanced transaminases, septic shock, CSS and MOF. It could be concluded that
COVID-19 systemic inflammation would be a part of hyperferritinemia syndrome [280,281]. It has been hypothesized that deferoxamine would be helpful in the management of COVID-19 due to its in vitro and in vivo
immunomodulatory and antiviral effects. Also, deferoxamine can reduce viral replication through the induction of
the iron deprivation that is a crucial element in the SARS-CoV-2 replication process [282,283]. So, iron chelating
agents such as deferoxamine would be notable supportive therapy in the treatment of critically ill COVID-19
patients. However, randomized, controlled trials are required to authorize the risks and benefits of deferoxamine
administration in the management of COVID-19 patients.
Metformin
Metformin, a biguanide antidiabetic agent, has been recently introduced as a promising therapeutic agent in
COVID-19 pneumonia patients with underlying Type 2 diabetes mellitus (DM) due to its pleiotropic effects.
The possible mechanisms of metformin in COVID-19 management were subjected to control blood sugar
levels, body weight reduction, diminished insulin resistance and prevent hyperactivation immune responses. ARDS
is likely prevented through inhibition of the mammalian target of rapamycin pathway and neutrophil reduction.
Additionally, the blockade of mitochondrial ROS signaling pathway can occur through cellular pH enhancement via
endosomal Na+ /H+ exchangers and interference with viral endocytosis [284]. Viral penetration inhibition through
the activation of mitogen-activated protein kinase (AMPK) and phosphorylation of ACE2 at Ser680 residue in
human umbilical vein endothelial cells has been suggested. This phosphorylation process can induce steric hindrance
and prevent the binding of ACE2 to the SARS-CoV-2 receptor-binding domain [285,286]. ACE2, a peptide with
anti-inflammatory properties, is considered as a protective marker in the renin-angiotensin-aldosterone system
(RAAS) with several beneficial cardiopulmonary effects [287–289]. Also, it has been hypothesized that metformin can
reverse COVID-19-induced lung fibrosis [284]. Results of some observational and retrospective studies revealed that
metformin administration in DM patients hospitalized due to COVID-19 infection decreased fatality rates [290–292].
Although DM has been considered an important risk factor for COVID-19, it seems that in COVID-19 cases with
DM who were receiving metformin as an antidiabetic agent, minor lung injury and ARDS have occurred due to the
protective role of metformin in AMPK activation and ACE2 phosphorylation, which results in an ACE2 extended
half-life and higher circulating ACE2 levels [288]. So, it seems that metformin would be a potential therapeutic
agent in patients in acute chronic or recovery stages of COVID-19, but more extensive, controlled trials are needed
to prove it is efficacious in COVID-19 management among both diabetic and nondiabetic patients. Finally, it has
been warned that the administration of metformin in COVID-19 patients should be discontinued promptly if
severe GI effects, hypoxia, lactic acidosis of MOF occur [287].
Mesenchymal stem cells

Mesenchymal stem cells (MSCs) are multipotent cells that would be considered in many inflammatory and
immunologic diseases. The most common sources of MSC transplantation are the umbilical cord, bone marrow
and adipose tissue. The possible mechanism of MSC therapy in COVID-19 management is by initiating MSC
differentiation [293]. Also, MSC therapy could induce tissue repair through various mechanisms, including secretion
of anti-inflammatory cytokines, angiogenesis induction, immunomodulatory potential and extracellular vesicle
release. MSC could induce its innate and adaptive immunomodulatory capacities through the secretion of soluble
factors, such as nitric oxide (NO), TGF-ß1 and PGE2, that can inhibit the maturation of dendritic cells and
block the function of lymphocytes such as T-cells, B-cells and NK cells and ameliorate symptoms of COVID-19induced ARDS [293]. It has been hypothesized that dsRNA of SARS-CoV-2 could induce the immunomodulatory
effects of MSC through the enhancement of Toll-like receptor on MSC. It has also been reported that perfusion
of 1 × 106 cells/kg through MSC transplantation could ameliorate all clinical symptoms related to COVID-
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19 pneumonia [294]. Recent studies evaluating the MSC efficacy in Chinese patients revealed that MSC therapy
(infusion of 7 × 106 cells/kg allogeneic human umbilical cord MSC) could significantly induce symptom reversal
with no severe adverse reactions [295,296]. Since MSCs could express low levels of human leukocyte antigens, they
can be used as allogenic transplantation to manage acute inflammatory disorders. They are capable of relieving
lung injury about 30 minutes after intravenous perfusion by preventing accumulation in the pulmonary vascular
area. MSCs are capable of directly transferring mitochondrial cells to respiratory alveolar epithelial cells. They also
have the potential to repair ARDS-induced alveolar capillary wall damage via the secretion of FGF7 and Ang1. An
important advantage of MSC therapy is its potential to promote and suppress inflammatory responses based on
the environmental situation. Hence, MSC therapy could be an option in the management of severe COVID-19
cases that progress to ARDS, septic shock, CSS and MOF, especially in heart, kidney and lung injury cases [293].
A study from China revealed that MSC therapy in patients with severe infection (COVID-19) was accompanied
by a decrease in immune system overactivation and a decrease in lung repair through the induction of the lung
microenvironment process [297]. A recent study on assessment of MSC therapy’s efficacy and safety in COVID-19
management revealed that inflammatory indices such as WBC, pro-calcitonin, CRP and IL-6 were unchanged
after MSC perfusion; IgG and IgM were also unchanged after MSC therapy. Still, lactate, cardiac troponin T and
creatinine kinase MB were significantly increased [298]. According to this study, all severe cases recovered after MSC
therapy. Only three cases experienced therapy-related adverse reactions, including hepatic dysfunction, skin rash
and heart failure. So, MSC therapy would be considered an alternative therapy for critically ill COVID-19 patients
who progressed to ARDS. Caution is required in cases with metabolic acidosis and coronary heart disease (CHD).
Furthermore, the infusion rate should be slow enough to avoid heart failure incidence during MSC perfusion [298].
A summary of possible COVID-19 treatment is given in Table 4.
Latest recommendations on potential COVID-19 treatment options
Although numerous drugs and clinical trials have been reviewed in this paper, due to this pandemic’s economic,
social and health concerns, an appropriate selection of therapeutic regimens according to a patient-specific status is
essential. So, early diagnosis, close patient monitoring and the selection of appropriate therapeutic options based
on disease severity should be scheduled. In this regard, a list of recommended therapeutic regimens for COVID-19
management based on the severity of the infection and stage of the disease is given in Table 5 according to the latest
version of the NIH COVID-19 treatment guidelines [299].
An overview of existing drugs in the treatment of COVID-19 is illustrated in Figure 5. HQ and bromhexine
prevent the virus from entering the human body. Corticosteroids inhibit CSS, and thalidomide reduces oxidative
stress and TNF-α, IL-1 and IL-6 production. Anti-IL-6 monoclonal antibody (siltuximab) and anti-IL-6 receptor
monoclonal antibodies (tocilizumab and sarilumab) reduce CSS. IVIG immediately enhances blood IgG levels that
can neutralize SARS-CoV-2 exogenous antigens. IFN-α and IFN-β can directly affect virus particle replication
and viral protein synthesis and can diminish virus release from infected host cells. Antiviral drugs (remdesivir,
favipiravir, lopinavir/ritonavir) prevent transcription of the RNA virus.
Conclusion
The new COVID-19 rapidly spread around the world, and because of a high transmission rate, it became a pandemic
within a few months. Many people suffer from this disease, and over 5 million deaths have been recorded. COVID19 created one of the greatest global economic crises in history. The economic crises and control measures negatively
impacted businesses and working conditions and highlighted inequalities in several communities. Although the
first COVID-19 vaccine was administered in December 2020, immunization of 7.8 billion people worldwide is
challenging due to the limited supply of vaccines and the new strains of the virus. In order to control and mitigate
COVID-19, as well as address the immediate and long-term health outcomes, it is essential to have comprehensive
information about the nature of COVID-19: its evolution, characteristics, mode of action and transmission. Due
to the circulation of highly transmissible variants, more infections are likely, and unvaccinated people are most at
risk. No vaccine is 100% effective; a small percentage of vaccinated people can also become infected, and some
breakthrough infections are to be expected. As the delta variant of the coronavirus spreads globally, it is important
to develop efficient therapeutic strategies to protect infected patients against severe illness, hospitalization and
death. To better understand the risk factors related to epidemic-prone diseases such as COVID-19, an in-depth
understanding of the ecological and genetic risk factors is required. One of the best ways to mitigate and prevent
transmission of emerging epidemic-prone diseases such as COVID-19 is to understand the virus and how it spreads
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Table 4. Classification of possible COVID-19 treatment mentioned in the “other treatment” section.
Drug

Administration

Mechanism of action

Contraindications

Major side effects

Convalescent
plasma
transfusion

iv.: the optimal dose is
unknown but the
recommended dose is
1–2 units
(≈200–250 ml/unit)

Neutralizing antibodies in convalescent plasma are
effective in SARS-CoV-2 clearance and induction of
passive immunity. Also, non-neutralizing antibodies
in convalescent plasma, such as IgM and IgG, could
induce protective and/or therapeutic effects
against COVID-19

No significant
contraindication

Transfusion reactions, including
allergic reaction, anaphylactic
reaction, transfusion-related
ALI, transfusion-associated
circulatory overload, hemolysis,
interference with SARS-CoV-2
vaccination, reduction in
efficacy of vaccination and
antibody-dependent
enhancement

IVIG

iv.; 0.3–0.5 g/kg/day
for 3–5 days

IVIG could act as an immunomodulator through the No significant
inhibition of pro-inflammatory cytokines. IVIG
contraindication
immediately enhances blood IgG levels that can
neutralize SARS-CoV-2 exogenous antigens. Also, it
can regulate immune media by enhancing the
capacity of natural immune cells and lymphocytes

Anaphylaxis reactions, TRALI,
thromboembolic events, acute
kidney injury, hemolysis and
hyponatremia

Vitamin C

iv.; 10–20 g/day
infusion over 8–10 h

Inhibition of IL-6 and TNF-␣ and regulation of the
production of T-cells, B-cells and NK cells and
reduction of the signaling responses of GM-CSF.
Also, there are some suggestions on the direct
viricidal effect of vitamin C

No significant
contraindication

Nephropathy and
nephrolithiasis

[274–276]

Deferoxamine

iv.; a loading dose of
1000 mg and then
500 mg q4h for two
other doses

An antidote of excess iron that could show
synergistic effects with antiviral agents such as
remdesivir in reducing the viral replication cycle

Hypersensitivity to
deferoxamine,
severe renal disease
and anuria

ARDS, infusion reactions and
acute kidney injury

[278,279]

MSC

iv.

MSC could stimulate the differentiation process and No significant
have immunomodulatory effects and induce tissue
contraindication
repair. MSC could induce its immunomodulatory
capacities through secretion of soluble factors,
including NO, TGF-ß1, PGE2 and so on, that can
block the maturation of dendritic cells

No significant adverse reactions

[293,295]

Metformin

Oral

Metformin could diminish insulin resistance,
prevent immune hyperactivation and ARDS
occurrence through the inhibition of the mTOR
pathway. Furthermore, it could show
anti-inflammatory effects and neutrophil reduction,
blockade of mitochondrial ROS signaling pathway,
cellular pH enhancement through endosomal
Na+/H+ exchangers.The interference with viral
endocytosis and viral penetration inhibition
through the activation of MAPK and
phosphorylation of ACE2 are among other
metformin actions

GI side effects including
diarrhea, nausea, and vomiting;
flushing; chest pain;
palpitations and lactic acidosis

[284–286]

Severe renal failure
(GFR ⬍30); acute or
chronic metabolic
acidosis with or
without coma,
including DKA; and
severe hepatic
failure

Ref.
[238,265]

[238,270,272]

ALI: Acute lung injury; ARDS: Acute respiratory distress syndrome; ACE2: Angiotensin-converting enzyme 2; GFR: Glomerular filtration rate; is a test used to check how well the kidneys
are working, IgG: Immunoglobulin G; IgM: Immunoglobulin M; IVIG: Intravenous immunoglobulin; MAPK: Mitogen-activated protein kinase; mTOR: Mammalian target of rapamycin;
MSC: Mesenchymal stem cells; NO: Nitric oxide, PGE2: Prostaglandin E2; ROS: Reactive oxygen species.

early on to enable quick intervention strategies. Concerted efforts among communities are vital for this effort. To
sum up, regarding the vast spread of COVID-19 worldwide, efficacious medical treatment against COVID-19
should remain a priority to control the growing epidemic and treat COVID-19 patients.
Future perspective
The COVID-19 pandemic has proven to be an unprecedented catastrophe affecting all ages, races and countries.
The outbreak has taken millions of lives and has dramatically affected all aspects of our lives from health to economic.
Although different platforms of vaccines have been developed and administered globally, not all residents have been
fortunate to receive them. The more transmittable the virus becomes, the harder it is to achieve community-level
protection. Two distinct kinds of advantages can be obtained from immunizing individuals. For any one person,
the vaccine does protect against getting the illness, and it protects against severe illness, reduces hospitalization and
decreases death rate. Additionally, community protection, sometimes referred to as herd immunity, is also achieved.
More specifically, herd immunity refers to many people with an increased level of individual protection that the
virus cannot find enough susceptible new individuals to infect and gradually diminishes, eventually disappearing
in circulation in the community. To date, only about 51% of people worldwide have received their first dose, and
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Table 5. A summary of the latest recommendations on potential COVID-19 treatment options.
Therapeutic options

Latest status

Comments

Remdesivir

FDA has recommended the use

FDA approved for the management of hospitalized COVID-19 patients (elderly and
pediatrics with an age ≥12 years old and a weight ≥40 kg)

CQ or HCQ ± AZN

Recommended against the use

Ivermectin

Recommended against its use

Only use in the context of clinical trials

LPV/ritonavir and other HIV
protease inhibitors

Recommended against its use

Only use in the context of clinical trials

Convalescent plasma

Insufficient data available in support of its
use or against the use

Ig: SARS-CoV-2 specific

Inadequate data available in support of
SARS-CoV-2 Ig use or against the use

Ig: non-SARS-CoV-2 specific

Recommended against the use

Only use in the context of clinical trials; administration of IVIG in management of
complications that may occur during the course of a COVID-19 infection, that should
not be precluded

MSCs

Recommended against the use

Only use in the context of clinical trials

Corticosteroids

Use of dexamethasone (other
glucocorticoids) ± remdesivir
recommended

Indicated for cases with severe COVID-19 who may also exhibit SIRS, ARDS, multi-organ
dysfunction and lung injury

Anakinra

Inadequate data available to either suggest
the use or recommend against the use of
anakinra

IFN-␤

Inadequate data available to either suggest Only use in mild and moderate COVID-19 infection and ⬍7 days from onset of signs
the use or recommend against the use of
and symptoms in the context of clinical trials
IFN-␤

Anti-IL-6 mAB (siltuximab) and
anti-IL-6 receptor monoclonal
antibodies (tocilizumab and
sarilumab)

Recommended against the use

According to the REMAP-CAP trial, a single dose of tocilizumab (8 mg/kg; max: 800 mg)
might be considered as an adjunctive therapy in combination with dexamethasone in
patients who are within first 24 h ICU admission and require mechanical ventilation
and patients who experience rapid progression to respiratory failure

IFN-␣ or ␤

Recommended against the use in severely
and critically ill COVID-19 patients

Only used in the context of clinical trials

BTK inhibitors (acalabrutinib,
ibrutinib, zanubrutinib)

Use not recommended

Only use in the context of clinical trials

Antithrombotic therapy

Consider therapy based on patient’s status

In outpatient setting of COVID-19 management, anticoagulants/antiplatelet treatment
should not be started for the prevention of thrombotic events. For hospitalized
COVID-19 patients, prophylactic anticoagulation should be considered unless
contraindications recorded for the patient

Vitamin C

Insufficient data available

Vitamin D

Insufficient data available

Zinc supplementation

Insufficient data available

AZN: Azithromycin; ARDS: Acute respiratory distress syndrome; BTK: Bruton tyrosine kinase; CQ: Chloroquine; HCQ: Hydroxychloroquine; Ig: Immunoglobulin; IVIG: Intravenous immunoglobulin; LPV: Lonapiravir; mAB: Monoclonal antibody, MSCs: Mesenchymal stem cells; REMAP-CAP: A randomized, embedded, multi-factorial, adaptive platform trial for communityacquired pneumonia; SIRS: Systemic inflammatory response syndrome.

nearly 40% have received the second dose, which indicates slow vaccination rates. It will take vaccination rates
of about 70–85% to reach the herd immunity threshold and bring this pandemic to an end. If we do not reach
the herd immunity threshold by next winter, COVID-19 may resurface as a seasonal virus. Due to the limited
capacity of production of the vaccine in some countries and fast transmission rates, an important concern is the
incidence of new viral mutant strains and their resistance to current vaccines. To meet global demands, vaccine
production technology can be transported from developed countries to developing countries. Oxford AstraZeneca
has worked with countries such as India and more recently with South Korea in this effort. Also, health education
leaders are facing a serious challenge regarding vaccine hesitancy. It will be difficult for people who do not have
sufficient knowledge of health systems to accept that an attenuated virus is to be injected into their body in the
form of a vaccine; therefore, it presents resistance to vaccination. To overcome this challenge, educating the public
about vaccines is essential. Another important issue to consider is that a percentage of breakthrough cases have been
reported, highlighting the importance of having efficient therapeutic strategies for dealing with infected patients. It
is likely that we will encounter a virus with greater lethality and wider spread in the future. It goes without saying
that the capacity to produce modern vaccines, to help advance the production of nanoparticle-based vaccines and
provide general knowledge to international communities must be prioritized by world governments. Hence, in the
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Figure 5. Schematic illustration of different types of SARS-CoV-2 treatments and mechanisms of action. The various
repurposed drugs and novel therapeutic approaches undergoing clinical trial against COVID-19 in the context of host
pathways and virus replication mechanisms are summarized [300]. Hydroxychloroquine prevents the virus from
entering the human body. Thalidomide reduces oxidative stress and TNF-α, IL-1 and IL-6 production. Anti-IL-6
monoclonal antibody (siltuximab) and anti-IL-6 receptor monoclonal antibody (sarilumab) reduce cytokine storm
syndrome (CSS). Intravenous immunoglobulin (IVIG) immediately enhances blood immunoglobulin G (IgG) levels that
can neutralize SARS-CoV-2 exogenous antigens. IFN-α and IFN-β can directly affect virus particle replication and viral
protein synthesis and can diminish virus release from infected host cells. Antiviral drugs (remdesivir, favipiravir,
lopinavir/ritonavir) prevent transcription of the RNA virus [300].

current scenario, we still need to rely on preventive measures as well as smart therapeutic plans. Along with the
application of repurposed drugs used to manage COVID-19, the development of specific anti-COVID-19 drugs
is necessary. In case the virus is not eradicated, therapeutic strategies will remain a pivotal tool for the future.
Executive summary
Epidemiology
• The coronavirus is a kind of virus that contains RNA genome and nucleocapsid phosphoprotein, which causes
many respiratory diseases in humans and various ranges of diseases in animals.
• The epidemiological trends in the outbreak and fatality rate of COVID-19 vary from day to day, and new mutants
of the virus were reported.
Antiviral agents
• Among the antiviral agents used in managing the COVID-19 crisis, favipiravir as a purine nucleic acid analog is
used to shorten the clearance time of the virus from the body. Also, remdesivir was shown to be capable of
inhibiting the virus with higher sensitivity and lower concentration.
Antibiotics
• Azithromycin is a macrolide that is effective in both Gram-negative and Gram-positive bacteria and is used to
treat respiratory tract infections. However, to date, there is no reliable clinical proof for the success of
azithromycin in COVID-19.
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Antiparasitic agents
• Among the antiparasitic agents used in COVID-19, ivermectin can reduce the infectivity of coronavirus through
binding to imp-α and imp-β1 proteins.
Nonsteroidal anti-inflammatory drugs
• Ibuprofen and naproxen as NSAIDs are used to suppress inflammation, fever and pain in the COVID-19 crisis. The
virus must bind to angiotensin-converting enzyme 2 receptors to enter eukaryotic cells. These drugs inhibit the
virus from attaching to the receptor. However, there is a great deal of disagreement about NSAIDs to improve
patients’ condition.
Mucolytic agents
• Among the mucolytic agents used in COVID-19, N-acetylcysteine and bromhexine help reduce mucus secretion.
N-acetylcysteine leads to a reduction in disulfide bonds. These drugs also prevent the attachment of viruses to the
angiotensin-converting enzyme 2 receptors.
Immunomodulatory drugs
• The administration of immune modulators could be a promising approach to circumvent harmful immunological
responses. For instance, anakinra as an IL-1 antagonist is an effective immune modulator that can eliminate the
requirement for mechanical ventilation in COVID-19 patients.
Corticosteroids
• It is supposed that keeping a balance between immune response and viral replication and infection should be
considered. So, the administration of corticosteroids may be beneficial in avoiding cytokin storm. However, there
are some controversy regarding the use of corticosteroids in COVID-19 patients.
Immunosuppressant drugs
• Among the immunosuppressant drugs, fingolimod can influence the aggregation and distribution of
lymphocytes. Moreover, leflunomide can shorten the duration of virus shedding and hospitalization.
Monoclonal antibodies
• To suppress the release of cytokine storm and activation of immune responses, monoclonal antibodies are used to
bind to the pivotal inflammatory cytokines and inhibit organ damage. For example, tocilizumab and sarilumab as
inhibitors of IL-6 can be promising options in alleviating symptoms in COVID-19 patients.
Anticoagulants
• The activation of innate immunity during viral replication leads to the activation of immune-thrombosis.
Therefore, it is thought that anticoagulants such as low molecular weight heparin and rivaroxaban can reduce
the risk of thrombosis while enhancing microcirculation and preventing organ damage.
Cardioprotective agents
• The administration of some cardioprotective agents, such as aspirin and statins, before hospitalization can reduce
mortality rates from acute lung injury and acute respiratory distress syndrome.
Other treatments
• It is suggested that SARS-CoV-2 can damage hemoglobin molecules. Hence, iron overload would be a common
consequence of SARS-CoV-2 infection. Therefore, deferoxamine, which acts as a chelating agent may benefit
these patients. Also, deferoxamine can reduce viral replication in the SARS-CoV-2 replication process. However,
randomized, controlled trials are required in the management of COVID-19 patients.
Mesenchymal stem cells
• The possible mechanism of mesenchymal stem cell therapy in COVID-19 management would be through
stimulation of the differentiation process and its immunomodulatory effects. Also, it could induce tissue repair
through various mechanisms, including the secretion of anti-inflammatory cytokines, angiogenesis induction,
immunomodulatory potential and extracellular vesicle release.

Acknowledgments
F Farjadian would like to thank the Research Council of Shiraz University for supporting this work.
Financial & competing interests disclosure
This work was supported by the Research Council of Shiraz University under COVID-19 special projects, grant no. 98-01-10622079. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial
interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.

1440

Future Microbiol. (2021) 16(18)

future science group

Drug-based therapeutic strategies for COVID-19-infected patients & their challenges

Review

References
Papers of special note have been highlighted as: • of interest; •• of considerable interest
1.

Bavinger JC, Shantha JG, Yeh S. Ebola, COVID-19, and emerging infectious disease: lessons learned and future preparedness. Curr.
Opin. Ophthalmol. 31(5), 416–422 (2020).

2.

Roychoudhury S, Das A, Sengupta P et al. Viral pandemics of the last four decades: pathophysiology, health impacts and perspectives.
Int. J. Environ. Res. Public Health 17(24), 9411 (2020).

3.

Paules CI, Marston HD, Fauci AS. Coronavirus infections – more than just the common cold. JAMA 323(8), 707–708 (2020).

4.

Ghasemiyeh P, Borhani-Haghighi A, Karimzadeh I et al. Major neurologic adverse drug reactions, potential drug–drug interactions and
pharmacokinetic aspects of drugs used in COVID-19 patients with stroke: a narrative review. Ther. Clin. Risk Manag. 16, 595 (2020).

5.

Tarus B, Bertrand H, Zedda G, Di Primo C, Quideau S, Slama-Schwok A. Structure-based design of novel naproxen derivatives
targeting monomeric nucleoprotein of influenza A virus. J. Biomol. Struct. Dyn. 33(9), 1899–1912 (2015).

6.

Padhi AK, Tripathi T. Targeted design of drug binding sites in the main protease of SARS-CoV-2 reveals potential signatures of
adaptation. Biochem. Biophys. Res. Commun. 555, 147–153 (2021).

7.

Padhi AK, Tripathi T. Can SARS-CoV-2 accumulate mutations in the S-protein to increase pathogenicity? ACS Pharmacol. Transl. Sci.
3(5), 1023–1026 (2020).

8.

Mahmoud DB, Shitu Z, Mostafa A. Drug repurposing of nitazoxanide: can it be an effective therapy for COVID-19? J. Genet. Eng.
Biotechnol. 18(1), 1–10 (2020).

9.

Struyf T, Deeks JJ, Dinnes J et al. Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings
has COVID-19 disease. Cochrane Database Syst. Rev. 7(7), CD013665 (2020).

10. Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines—a new era in vaccinology. Nat. Rev. Drug Discovery 17(4), 261–279
(2018).
11. Turner JS, O’halloran JA, Kalaidina E et al. SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses. Nature
596(7870), 109–113 (2021).
12. Lundstrom K. Viral vectors for COVID-19 vaccine development. Viruses 13(2), 317 (2021).
13. Kalita P, Padhi AK, Zhang KYJ, Tripathi T. Design of a peptide-based subunit vaccine against novel coronavirus SARS-CoV-2. Microb.
Pathog. 145, 104236 (2020).
14. World Health Organization. COVID-19 vaccines (2021).
http://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines
15. Kordzadeh-Kermani E, Khalili H, Karimzadeh I. Pathogenesis, clinical manifestations and complications of coronavirus disease 2019
(COVID-19). Future Microbiol. 15(13), 1287–1305 (2020).
16. Hoehl S, Rabenau H, Berger A et al. Evidence of SARS-CoV-2 infection in returning travelers from Wuhan, China. N. Engl. J. Med.
382(13), 1278–1280 (2020).
17. Billah MA, Miah MM, Khan MN. Reproductive number of coronavirus: a systematic review and meta-analysis based on global level
evidence. PLoS ONE 15(11), e0242128 (2020).
18. Wang M, Cao R, Zhang L et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in
vitro. Cell Res. 30(3), 269–271 (2020).
19. Yang SN, Atkinson SC, Wang C et al. The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β1
heterodimer. Antiviral Res. 177, 104760 (2020).
20. Meo SA, Al-Khlaiwi T, Usmani AM, Meo AS, Klonoff DC, Hoang TD. Biological and epidemiological trends in the prevalence and
mortality due to outbreaks of novel coronavirus COVID-19. J. King Saud. Univ. Sci. 32(4), 2495–2499 (2020).
21. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J. Autoimmun. 109,
102433 (2020).
22. Smith RD. Responding to global infectious disease outbreaks: lessons from SARS on the role of risk perception, communication and
management. Soc. Sci. Med. 63(12), 3113–3123 (2006).
23. Bai HX, Hsieh B, Xiong Z et al. Performance of radiologists in differentiating COVID-19 from viral pneumonia on chest CT. Radiology
296(2), e46–e54 (2020).
24. De Groot RJ, Baker SC, Baric RS et al. Commentary: Middle East Respiratory Syndrome coronavirus (MERS-CoV): announcement of
the coronavirus study group. J. Virol. 87(14), 7790–7792 (2013).
25. Mubarak A, Alturaiki W, Hemida MG. Middle East Respiratory Syndrome Coronavirus (MERS-CoV): infection, immunological
response, and vaccine development. J. Immunol. Res. 2019, 6491738 (2019).
26. Ghasemiyeh P, Mohammadi-Samani S. The necessity of early anti-inflammatory therapy initiation in cases with mild-to-moderate
COVID-19: a personal experience from an attending pharmacist and his resident. Acta Bio-medica: Atenei Parmensis 92(3),
e2021250–e2021250 (2021).

future science group

www.futuremedicine.com

1441

Review

Zarkesh, Entezar-Almahdi, Ghasemiyeh et al.

27. Hui DS, Azhar EI, Madani TA et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health—the latest
2019 novel coronavirus outbreak in Wuhan, China. J. Glob. Infect. Dis. 91, 264–266 (2020).
28. Clerkin KJ, Fried JA, Raikhelkar J et al. COVID-19 and cardiovascular disease. Circulation 141(20), 1648–1655 (2020).
29. Guo T, Fan Y, Chen M et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19).
JAMA Cardiol. 5(7), 811–818 (2020).
30. Mao L, Jin H, Wang M et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA
Neurol. 77(6), 683–690 (2020).
31. Filatov A, Sharma P, Hindi F, Espinosa PS. Neurological complications of coronavirus disease (COVID-19): encephalopathy. Cureus
12(3), e7352 (2020).
32. Wu P, Duan F, Luo C et al. Characteristics of ocular findings of patients with coronavirus disease 2019 (COVID-19) in Hubei Province,
China. JAMA Ophthalmol. 138(5), 575–578 (2020).
33. Galván Casas C, Catala A, Carretero Hernández G et al. Classification of the cutaneous manifestations of COVID-19: a rapid
prospective nationwide consensus study in Spain with 375 cases. Br. J. Dermatol. 183(1), 71–77 (2020).
34. Diaz-Guimaraens B, Dominguez-Santas M, Suarez-Valle A et al. Petechial skin rash associated with severe acute respiratory syndrome
coronavirus 2 infection. JAMA Dermatol. 156(7), 820–822 (2020).
35. Zu ZY, Jiang MD, Xu PP et al. Coronavirus disease 2019 (COVID-19): a perspective from China. Radiology 296(2), e15–e25 (2020).
36. Lippi G, Plebani M. Laboratory abnormalities in patients with COVID-2019 infection. Clin. Chem. Lab. Med. 58(7), 1131–1134
(2020).
37. Bai Y, Yao L, Wei T et al. Presumed asymptomatic carrier transmission of COVID-19. JAMA 323(14), 1406–1407 (2020).
38. Sallard E, Lescure F-X, Yazdanpanah Y et al. Type 1 interferons as a potential treatment against COVID-19. Antiviral Res. 178, 104791
(2020).
39. Huang C, Wang Y, Li X et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395(10223),
497–506 (2020).
40. Tillett RL, Sevinsky JR, Hartley PDet al. Genomic evidence for reinfection with SARS-CoV-2: a case study. Lancet Infect. Dis. 21(1),
52–58 (2021).
41. Iwasaki A. What reinfections mean for COVID-19. Lancet Infect. Dis. 21(1), 3–5 (2021).
42. Farjadian F, Ghasemi A, Gohari O, Roointan A, Karimi M, Hamblin MR. Nanopharmaceuticals and nanomedicines currently on the
market: challenges and opportunities. Nanomedicine 14(1), 93–126 (2019).
43. Farjadian F, Roointan A, Mohammadi-Samani S, Hosseini M. Mesoporous silica nanoparticles: synthesis, pharmaceutical applications,
biodistribution, and biosafety assessment. Chem. Eng. J. 359, 684–705 (2019).
44. Farjadian F, Moghoofei M, Mirkiani S et al. Bacterial components as naturally inspired nano-carriers for drug/gene delivery and
immunization: set the bugs to work? Biotechnol. Adv. 36(4), 968–985 (2018).
45. Ahmadi S, Rabiee N, Bagherzadeh M et al. Stimulus-responsive sequential release systems for drug and gene delivery. Nano Today 34,
100914 (2020).
46. Entezar-Almahdi E, Mohammadi-Samani S, Tayebi L, Farjadian F. Recent advances in designing 5-fluorouracil delivery systems: a
stepping stone in the safe treatment of colorectal cancer. Int. J. Nanomed. 15, 5445–5458 (2020).
47. Akbarian M, Yousefi R, Farjadian F, Uversky VN. Insulin fibrillation: toward strategies for attenuating the process. Chem. Commun.
56(77), 11354–11373 (2020).
48. Hosseini M, Farjadian F, Makhlouf ASH. Smart stimuli-responsive nano-sized hosts for drug delivery. In:Industrial Applications for
Intelligent Polymers and Coatings. Hosseini M, Makhlouf ASH (Eds). Springer, Cham, Switzerland,
doi:https://doi.org/10.1007/978-3-319-26893-4 1 (2016).
49. Du Y-X, Chen X-P. Favipiravir: pharmacokinetics and concerns about clinical trials for 2019-nCoV infection. Clin. Pharmacol. Ther.
108(2), 242–247 (2020).
50. Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL. Favipiravir (T-705), a novel viral RNA polymerase inhibitor.
Antiviral Res. 100(2), 446–454 (2013).
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163. Rassy D, Bárcena B, Pérez-Osorio IN et al. Intranasal methylprednisolone effectively reduces neuroinflammation in mice with
experimental autoimmune encephalitis. J. Neuropathol. Exp. Neur. 79(2), 226–237 (2020).
164. Zha L, Li S, Pan L et al. Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19). Med. J. Aust. 212(9), 416–420
(2020).
165. Ho C-M, Ho S-T, Wang J-J, Tsai S-K, Chai C-Y. Dexamethasone has a central antiemetic mechanism in decerebrated cats. Anesth.
Analg. 99(3), 734–739 (2004).
166. Giles AJ, Hutchinson M-KN, Sonnemann HM et al. Dexamethasone-induced immunosuppression: mechanisms and implications for
immunotherapy. J. Immunother. Cancer 6(1), 1–13 (2018).
167. Theoharides T, Conti P. Dexamethasone for COVID-19? Not so fast. J. Biol. Regul. Homeost. Agents 34(3), 10.23812 (2020).
168. Johnson RM, Vinetz JM. Dexamethasone in the management of COVID-19. Br. Med. J. 370, m2648 (2020).
169. Horby P, Lim WS, Emberson JR et al. Dexamethasone in hospitalized patients with COVID-19 – preliminary report. N. Engl. J. Med.
384(8), 693–704 (2020).
170. Gallagher C. The mechanism of action of hydrocortisone on mitochondrial metabolism. Biochem. J. 74(1), 38–43 (1960).
171. Pudrith C, Kim YH, Martin D et al. Effect of topical treatment of various glucocorticoids on lipopolysaccharide induced otitis media
with effusion in chinchilla. Int. J. Pediatr. Otorhinolaryngol. 74(11), 1273–1275 (2010).
172. Prete A, Taylor AE, Bancos I et al. Prevention of adrenal crisis: cortisol responses to major stress compared to stress dose hydrocortisone
delivery. J. Clin. Endocrinol. Metab. 105(7), 2262–2274 (2020).
173. Almeida MQ, Mendonca BB. Adrenal insufficiency and glucocorticoid use during the COVID-19 pandemic. Clinics 75, e2022 (2020).
174. Reynolds NA, Perry CM, Keating GM. Budesonide/formoterol. Drugs 64(4), 431–441 (2004).
175. Health NIO. Global Initiative for Asthma. Global strategy for asthma management and prevention. NHLBI/WHO work shop report
(1995).
176. Halpin DM, Singh D, Hadfield RM. Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective. Eur. Respir. J.
55(5), 2001009 (2020).
177. Wu Z, Mcgoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China:
summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA 323(13), 1239–1242 (2020).
178. Szafranski W, Cukier A, Ramirez A et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive
pulmonary disease. Eur. Respir. J. 21(1), 74–81 (2003).
179. Yang M, Zhang Y, Chen H, Lin J, Zeng J, Xu Z. Inhaled corticosteroids and risk of upper respiratory tract infection in patients with
asthma: a meta-analysis. Infection 47(3), 377–385 (2019).
180. Lipworth B, Kuo CR, Lipworth S, Chan R. Inhaled corticosteroids and COVID-19. Am. J. Respir. Crit. Care Med. 202(6), 899–900
(2020).
181. Ingwersen J, Aktas O, Kuery P, Kieseier B, Boyko A, Hartung H-P. Fingolimod in multiple sclerosis: mechanisms of action and clinical
efficacy. Clin. Immunol. 142(1), 15–24 (2012).
182. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review.
JAMA 323(18), 1824–1836 (2020).
183. Fox RI, Herrmann ML, Frangou CG et al. Mechanism of action for leflunomide in rheumatoid arthritis. Clin. Immunol. 93(3), 198–208
(1999).
184. Xiao K, Hou F, Huang X, Li B, Qian ZR, Xie L. Mesenchymal stem cells: current clinical progress in ARDS and COVID-19. Stem Cell
Res. Ther. 11(1), 305 (2020).
185. Amirshahrokhi K. Anti-inflammatory effect of thalidomide in paraquat-induced pulmonary injury in mice. Int. Immunopharmacol.
17(2), 210–215 (2013).
186. Dong X, Li X, Li M, Chen M, Fan Q, Wei W. Antiinflammation and antioxidant effects of thalidomide on pulmonary fibrosis in mice
and human lung fibroblasts. Inflammation 40(6), 1836–1846 (2017).
187. Dastan F, Tabarsi P, Marjani M et al. Thalidomide against coronavirus disease 2019 (COVID-19): a medicine with a thousand faces.
Iran J. Pharmaceut. Res. 19(1), 1–2 (2020).
188. Zhu H, Shi X, Ju D, Huang H, Wei W, Dong X. Anti-inflammatory effect of thalidomide on H1N1 influenza virus-induced pulmonary
injury in mice. Inflammation 37(6), 2091–2098 (2014).
189. Peng H, Gong T, Huang X et al. A synergistic role of convalescent plasma and mesenchymal stem cells in the treatment of severely ill
COVID-19 patients: a clinical case report. Stem Cell Res. Ther. 11(1), 1–6 (2020).
190. Sebba A. Tocilizumab: the first interleukin-6-receptor inhibitor. Am. J. Health-Syst. Pharm. 65(15), 1413–1418 (2008).

future science group

www.futuremedicine.com

1447

Review

Zarkesh, Entezar-Almahdi, Ghasemiyeh et al.

191. Khiali S, Khani E, Entezari-Maleki T. A comprehensive review of tocilizumab in COVID-19 acute respiratory distress syndrome. J. Clin.
Pharmacol. 60(9), 1131–1146 (2020).
192. Alzghari SK, Acuña VS. Supportive treatment with tocilizumab for COVID-19: a systematic review. J. Clin. Virol. 127, 104380 (2020).
193. Jain S, Sharma SK. Rational use of tocilizumab in COVID-19. Ann. Rheum. Dis. Doi:10.1136/annrheumdis-2020-218519. (2020)
(Epub ahead of print).
194. Fajgenbaum DC, June CH. Cytokine storm. N. Engl. J. Med. 383(23), 2255–2273 (2020).
195. Fu B, Xu X, Wei H. Why tocilizumab could be an effective treatment for severe COVID-19? J. Transl. Med. 18(1), 164 (2020).
196. Xu X, Han M, Li T et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc. Natl Acad. Sci. 117(20),
10970–10975 (2020).
197. Zhang S, Li L, Shen A, Chen Y, Qi Z. Rational use of tocilizumab in the treatment of novel coronavirus pneumonia. Clin. Drug Invest.
40(6), 511–518 (2020).
••

This article elaborates the role of cytokine storm in COVID-19 and the mechanism of action of tocilizumab on cytokine storm.

198. Samaee H, Mohsenzadegan M, Ala S, Maroufi SS, Moradimajd P. Tocilizumab for treatment patients with COVID-19: recommended
medication for novel disease. Int. Immunopharmacol. 89, 107018 (2020).
199. Scott LJ. Sarilumab: first global approval. Drugs 77(6), 705–712 (2017).
200. Della-Torre E, Campochiaro C, Cavalli G et al. Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic
hyperinflammation: an open-label cohort study. Ann. Rheum. Dis. 79(10), 1277–1285 (2020).
•

It is an open-label cohort study that showed sarilumab was associated with faster recovery in patients showing minor lung
consolidation at baseline.
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